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OBIETTIVI E SOMMARIO  
L’attività di ricerca del Dottorato si è svolta presso la Clinica di Oncoematologia 
Pediatrica del Dipartimento di Pediatria dell’Università degli Studi di Padova. 
Il programma del dottorato si è sviluppato in un contesto di ricerca clinica ai fini dello 
studio di “nuove” strategie terapeutiche per i pazienti pediatrici affetti da tumori solidi 
recidivi/refrattari.  
Il Nostro Centro costituisce uno dei maggiori Centri di Emato-Oncologia pediatrica in 
Italia ed è il Centro Coordinatore per i sarcomi delle parti molli a livello Nazionale. 
In Italia esiste, come è noto, una rete di rapporti tra i centri di Emato-Oncologia 
Pediatrica che permette di seguire i bambini affetti da patologia neoplastica in modo 
omogeneo e coordinato. La partecipazione attiva ai Protocolli terapeutici 
dell’Associazione Italiana di Emato-Oncologia Pediatrica (AIEOP) e il contributo 
costante nell’ elaborazione dei Protocolli stessi da parte del Nostro Centro, costituisce 
uno dei punti fermi dell’attività clinica e scientifica. Per quanto attiene alla patologia in 
discussione (tumori solidi dell’infanzia), il Nostro Centro ha inoltre funzioni di 
coordinamento a livello europeo nell’ambito del protocollo per la cura dei sarcomi delle 
parti molli EpSSG 2005. 
Il Nostro Centro nell’attività scientifica e clinica quotidiana collabora, tra gli altri, con:  
• AIEOP: Associazione Italiana di Emato-Oncologia Pediatrica 
• EpSSG: European Protocol Soft Tissue Sarcoma Group 
• EPOC: European Paediatric Oncology Off-patent Medicines Consortium 
• INT Mi: Istituto Nazionale Tumori di Milano 
• IOV: Istituto Oncologico Veneto 
• ITCC: Innovative Therapies for Children with Cancer 
Il nostro lavoro si è pertanto concentrato sui pazienti in età pediatrica, adolescenziale e 
del giovane adulto affetti da tumore solido (in particolare Rabdomiosarcoma 
recidivo/refrattario). 
Una prima parte del lavoro si è focalizzata sullo studio della popolazione di pazienti 
adolescenti affetti da rabdomiosarcoma (RMS) e trattati secondo i protocolli del soft 
tissue sarcoma commitee (STSC) (1).  
Una seconda parte del Dottorato è stata dedicata all’analisi dei risultati ottenuti dai 
pazienti affetti da RMS trattati in seconda linea con il regime Topotecan/Carboplatino 
(2).  
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Fin dall’inizio dell’attività di Dottorato, visti gli obiettivi dello stesso, è iniziata una 
formazione specifica nell’ambito dei trials clinici, con partecipazione a corsi ad hoc, 
formazione di un gruppo di lavoro sui nuovi farmaci e apertura del nostro Centro a 
numerosi trials (3.2). 
A “conclusione” di questo iter gli sforzi sono stati coordinati alla stesura di un 
protocollo di fase II per pazienti affetti da recidiva meningea di RMS/PNET. Il 
protocollo è in fase di stesura, verrà presentata l’attuale bozza (3.3). 
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1 GLI ADOLESCENTI 
 
1.1 Introduzione 
 
La Comunità Scientifica ha mostrato negli ultimi anni un crescente interesse per quella 
che viene definita “Adolescent and Young Adult Oncology” (AYA) (1). Dati 
epidemiologici delle ultime decadi mostrano per la fascia d’età 15-45 anni di pazienti 
oncologici i peggiori risultati in termini di outcome/sopravvivenza. L’analisi del SEER 
(Survival, Epidemiology and End Results) relativa ai dati di sopravvivenza da tumore in 
base all’età (1975-1997), ha mostrato un miglioramento annuale del tasso di 
sopravvivenza a 5 anni superiore all’1,5% per i pazienti di età <15 anni e >50 anni, a 
fronte di un tasso <0,5% tra i 15-24 anni, assenza di miglioramento tra i 24-35 anni 
(vedi grafico) (2, 3).  
 
 
 
 
 
Tali risultati sono oggetto di ampio dibattito; uno dei principali fattori chiamati in causa 
a motivare questi pessimi risultati è la scarsa partecipazione dei pazienti adolescenti e 
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giovani adulti nei trials clinici; in effetti il tasso di arruolamento nei trials clinici in base 
all’età riflette l’andamento prognostico degli stessi pazienti (vedi grafico) (3, 4, 5, 6). 
 
 
 
 
 
Altri fattori considerati importanti sono: una maggior aggressività biologica a parità di 
patologia (7, 8); ritardi diagnostici dovuti sia al paziente che ai professionisti della 
salute (il primo riluttante a esporre problematiche personali in una fase di maturazione 
complessa caratterizzata da senso di autonomia e “invincibilità”, i secondi per scarsa 
consapevolezza/conoscenza delle patologie oncologiche di questa fascia d’età) (3, 9).  
Questo gruppo di pazienti così complessi sia dal punto di vista sociale e psicologico che 
dal punto di vista dell’epidemiologia delle patologie oncologiche di cui sono affetti, 
risiedono in quella che viene definita un’area “grigia”, “no-man’s land”, a metà strada 
tra l’Oncologia Pediatrica e l’Oncologia dell’adulto. Infatti in questo gruppo emerge 
una “transizione” epidemiologica: diminuiscono le patologie oncologiche pediatriche 
(Wilms, medulloblastomi, rabdomiosarcomi,…) e aumenta l’incidenza di quelle tipiche 
dell’età adulta (es. carcinomi), l’una di competenza pediatrica, l’altra dell’oncologo 
dell’adulto (vedi grafico).  
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Emerge pertanto la necessità di una sensibilizzazione della Comunità per evitare ritardi 
che aggravano la prognosi di questi pazienti, aumentare il tasso di arruolamento nei 
trials clinici (eventualmente alzando l’età limite dei protocolli pediatrici), ma soprattutto 
risulta fondamentale la stretta collaborazione tra gli Oncologi dell’adulto e del bambino. 
Il nostro Centro sta via via rafforzando la gestione comune di questi pazienti, con 
partecipazione degli Oncologi dell’adulto a demand ai multidisciplinari settimanali del 
gruppo sarcomi parti molli/tumori solidi pediatrici e viceversa, allo scopo di potenziare 
una gestione veramente multidisciplinare del paziente adolescente/giovane adulto con 
patologia pediatrica e del paziente pediatrico con patologia dell’adulto.  
La peculiarità e l’interesse crescente per l’argomento ci ha spinti a condurre uno studio 
su una popolazione di pazienti pediatrici e adolescenti affetti da rabdomiosarcoma 
trattati secondo i protocolli del STSC. 
I risultati dello studio (reso possibile dalla collaborazione con i maggiori Centri italiani 
di Oncologia pediatrica) sono stati oggetto di presentazioni a Congressi e i dati sono 
stati pubblicati su Cancer. 2012 Feb 1;118(3):821-7. Rhabdomyosarcoma in 
adolescents: a report from the AIEOP Soft Tissue Sarcoma Committee. Bisogno G, 
Compostella A, Ferrari A, Pastore G, Cecchetto G, Garaventa A, Indolfi P, De Sio L, 
Carli M. 
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1.2 Rhabdomyosarcoma in Adolescents. A Report From the 
AIEOP Soft Tissue Sarcoma Committee 
 
Gianni Bisogno, MD, PhD1; Alessia Compostella, MD1; Andrea Ferrari, MD2; Guido 
Pastore, MD3; Giovanni Cecchetto, MD4; Alberto Garaventa, MD5; Paolo Indolfi, 
MD6; Luigi De Sio, MD7; and Modesto Carli, MD1. 
 
BACKGROUND: In many types of cancer, the survival rates are reported to be less 
favorable for adolescents compared with younger children. To investigate whether this 
is true for adolescents with rhabdomyosarcoma (RMS), the results obtained in patients 
enrolled in protocols run by the Italian Soft Tissue Sarcoma Committee (STSC) were 
analyzed. METHODS: From 1988 through 2005, 643 patients were registered (567 
children ages birth-14 years and 76 adolescents ages 15-19 years) and treated in 4 STSC 
protocols. The number of patients enrolled was compared with the expected number 
calculated from incidence rates derived from the Italian network of cancer registries. 
RESULTS: Only 27% of the expected number of adolescents with RMS were enrolled 
in the STSC trials. Compared with children, adolescents were found to have a longer 
interval from initial symptoms to diagnosis (8 weeks vs 4.6 weeks), more alveolar RMS 
(47.4% vs 32.6%), lymph node infiltration (39.1% vs 23.3%), and metastases at the 
time of diagnosis (30.7% vs 17.8%). The 2 age groups received similar treatments. The 
5-year overall survival (OS) rate was 68.9% in children versus 57.2% in adolescents (P: 
0.006), and the progression-free survival (PFS) rate was 64.3% in children versus 
48.1% in adolescents (P: 0.0237). On multivariate analysis, age, tumor site, lymph node 
involvement, and metastases were found to be significant prognostic factors for OS and 
PFS. CONCLUSIONS: Survival for adolescents with RMS enrolled in STSC protocols 
appears to be satisfactory. The higher prevalence of unfavorable tumor characteristics 
noted among adolescents seems to explain their worse outcome compared with children. 
However, the limited number of adolescents enrolled in STSC studies is worrisome, and 
cooperation with oncologists who treat adults needs to be improved. 
Cancer 2011;000:000–000. VC 2011 American Cancer Society. 
 
KEYWORDS: rhabdomyosarcoma, adolescents, soft tissue sarcoma, survival. 
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Rhabdomyosarcoma (RMS) is a rare tumor that typically affects children and 
adolescents, with an annual incidence of 4.3 cases per 1 million population aged <20 
years. Approximately 3 in 4 cases occur in children aged <10 years, with a peak 
incidence between ages 3 and 5 years and a second, smaller peak in adolescence, after 
which the incidence drops significantly with increasing age. Approximately 70% of 
patients with localized RMS can now be cured, but their outcome is influenced by 
various prognostic factors identified over the years and currently used for risk stratifica-
tion and risk-adapted treatment decisions (1). Along with other variables such as 
histology, local and distant invasiveness, and tumor site and size, the patient’s age has 
emerged as one of the most relevant factors, with older patients reported to have a 
worse prognosis (2,3). 
Among the various age groups, adolescents with cancer form a group with particular 
features. Several studies have shown that improvements in the survival rates achieved in 
recent years have been less satisfactory for adolescents and young adults compared with 
younger children (4,5). Among the reasons suggested to explain this phenomenon are 
the greater presence in adolescents of tumors with less favorable characteristics, delays 
in the diagnosis, and a low accrual of adolescents in clinical trials (5,6). 
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Department of Pediatrics, Padova University Hospital, Padova, Italy; 5Pediatric 
Hematology/Oncology Division, G. Gaslini Children’s Hospital, Genova, Italy; 
6Pediatric Oncology Service, Second University of Naples, Naples, Italy; 7Oncology 
Division, Bambin Gesù Hospital, Rome, Italy 
We thank Angela Scagnellato for data processing and Ilaria Zanetti and Angela De 
Paoli for the statistical analysis. 
DOI: 10.1002/cncr.26355, Received: February 15, 2011; Revised: April 18, 2011; 
Accepted: April 28, 2011, Published online in Wiley Online Library 
(wileyonlinelibrary.com). 
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To the best of our knowledge, no published studies to date have focused on adolescents 
with RMS. Therefore, we analyzed the clinical and demographic characteristics, 
treatment, and outcome for patients in this age group who were treated in the clinical 
trials coordinated by the Associazione Italiana di Ematooncologia Pediatrica (AIEOP) 
Soft Tissue Sarcoma Committee (STSC) between 1988 and 2005. Because age was not 
considered to be a factor for treatment stratification purposes, children and adolescents 
received the same treatment, making them an ideal population for evaluating the relative 
contributions of the above-mentioned factors. 
To our knowledge, no other multicenter or institutional protocols including adolescents, 
or even adults, with RMS were being run in parallel in Italy during the same period of 
time. 
 
MATERIALS AND METHODS 
 
Over the course of 18 years, patients were enrolled by AIEOP centers in 4 consecutive 
protocols: RMS-88 and RMS-96 for children and adolescents with localized RMS, and 
MMT4 and RMS4.99 for those with metastatic disease. Pretreated patients, patients 
with RMS as a second malignancy, or though for which no data were available were not 
considered eligible for the purpose of this analysis. Patients ages 15 years to 19 years 
were classified as adolescents, and those aged <15 years were classified as children. 
Details regarding surgery, radiotherapy, and chemotherapy had been collected 
prospectively and were reviewed for the purpose of the current study. Informed consent 
according to the local institutional guidelines was obtained at the time of a patient’s 
enrollment in each protocol. 
Disease was staged according to the TNM and Intergroup Rhabdomyosarcoma Study 
(IRS) systems. In the TNM system, T1 indicates tumors confined to the organ or tissue 
of origin and T2 lesions invade contiguous structures; T1 and T2 are further classified 
as A or B according to whether the tumor diameter is < 5 cm or > 5 cm, respectively. 
N1 indicates regional lymph node involvement. In the IRS system, group I defines 
completely excised tumors, group II indicates macroscopically resected tumors with 
microscopic residual disease and/or regional lymph node involvement, group III 
indicates macroscopic residual disease after incomplete resection or biopsy, and group 
IV is used to denote metastatic disease. 
 10 
 
Despite differences in the chemotherapy regimens used in the various protocols, the 
policy dictating the therapeutic decisions remained much the same over the years. 
Treatment was based on: 1) conservative surgery or biopsy at the time of diagnosis; 2) 
initial chemotherapy according to various regimens; 3) disease evaluation after the first 
3 or 4 courses of chemotherapy; 4) second-look surgery in the event of residual disease; 
and 5) adjuvant chemotherapy after initial or delayed radical surgery. Radiotherapy was 
used for patients considered to be at risk of developing local recurrence (IRS groups II, 
III, and IV). 
Various chemotherapeutic regimens were adopted over the years, based on the different 
protocols and the extent of disease. Briefly, in the RMS-88 study, vincristine and 
actinomycin D (VA regimen) were administered to patients in IRS group I, ifosfamide 
was added for patients in IRS group II (IVA), and doxorubicin (adriamycin) (VAIA) 
was added for patients in IRS group III. In the RMS-96 protocols, low-risk patients 
were treated with VA, standard-risk patients received IVA, and high-risk patients were 
randomized to receive either the VAIA or CEVAIE (carboplatin, epirubicin, vincristine, 
etoposide, ifosfamide, and actinomycin D) combinations; details of the chemotherapy 
regimens have been published elsewhere (7). 
Patients included in the MMT4 protocol received 4 cycles of the CEVAIE regimen. In 
1991, the protocol was amended and the fourth cycle was replaced with high-dose 
melphalan (200 mg/m2) with autologous peripheral blood stem cell rescue (8). Finally, 
in the RMS4.99 protocol, after the initial CEVAIE regimen, 3 consecutive cycles of 
high-dose chemotherapy were administered, followed by local treatment and 
maintenance chemotherapy with vincristine, actinomycin D, and cyclophosphamide (9). 
Response was formally evaluated after initial chemotherapy (week 9) and at the end of 
treatment and was defined as complete response (CR; clinically or histologically 
confirmed complete disappearance of disease); partial response (PR; at least a two-
thirds reduction in tumor volume); minor response (a greater than one-third but less than 
two-thirds reduction in tumor volume); no response or stable disease, or a less than one-
third reduction in tumor volume; and progressive disease (an increase in tumor size or 
the detection of new lesions). 
 
Patient Accrual 
The number of patients enrolled in the AIEOP protocols was compared with the number 
of cases expected to be diagnosed in Italy during the same period, based on incidence 
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data from the well-established Italian network of population-based cancer registries 
(AIRTUM), which pools data drawn from 22 general registries and 3 specialist 
registries (2 regarding childhood and adolescent cancer and 1 pertaining to female 
breast cancer) and covers 32.9% of children and 26.9% of adolescents residing in Italy 
(10). 
 
Statistical Analysis 
Survival curves were calculated using the Kaplan-Meier method. Overall survival (OS) 
was considered as the time from diagnosis to last follow-up or death because of any 
cause and progression-free survival (PFS) was considered as the time from diagnosis to 
first disease progression, recurrence, death because of any cause, or latest contact for 
children who never experienced an event. The logrank test was used to compare 
survival rates between different subgroups of patients by univariate analysis, 
considering patient characteristics (age and gender) and tumor features (histological 
subtype, site, size, invasiveness, lymph node involvement, and type and number of 
metastases). The different sites were grouped by prognosis as favorable (orbit, head and 
neck, and genitourinary non bladder/prostate) or unfavorable (parameningeal, extrem-
ities, bladder/prostate, and other sites). A P value <.05 was considered statistically 
significant. A multivariate analysis was conducted with the Cox proportional hazards 
regression method to determine the independent prognostic influence of pretreatment 
factors on survival, using the variables found to correlate with OS and PFS on uni-
variate analysis. The study was approved by the Ethics Committees of all the centers 
taking part and informed consent was obtained from all patients enrolled in the 
protocols. 
 
RESULTS 
 
Patients 
The clinical characteristics of the 643 patients considered for this analysis are shown in 
Table 1.  
A total of 567 patients were children (median age, 4.8 years) and 76 were adolescents 
(median age, 16.5 years). The male/ female ratio was 1.5 in children and 2.3 in 
adolescents. 
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A median of 4 adolescents (range, 1-8 adolescents) were registered each year during the 
study period, whereas 15.4 adolescent cases per year were expected according to the 
AIRTUM data (10). The observed-to-expected (O/E) ratio for adolescents with RMS 
was 0.27, whereas that for children was 0.9 during the same period. The number of 
adolescents registered for the STSC protocols increased progressively from 3.6 (1988-
1993) to 5.5 (2000-2005) cases per year. 
Data regarding the time elapsed between the onset of symptoms and diagnosis were 
available for 580 patients and ranged from 0 to 155 weeks (median, 5 weeks). The 
median diagnostic delay for children was 4.6 weeks (range, 0 weeks-155 weeks), which 
differed significantly (P < .0001) from the findings among adolescents, whose median 
latency period was 8 weeks (range, 0 weeks-74 weeks). 
The tumor characteristics differed in the 2 age groups. Adolescents had more cases of 
genitourinary non bladder/prostate tumors (36.8% vs 12.9% in children; P < .0001), 
alveolar histology (47.4% vs 32.6% in children; P = .01), lymph node involvement 
(35.5% vs 21.7% in children; P = .004), and metastases at the time of diagnosis (30.3% 
vs 17.8% in children; P = .008) (Table 1). 
 
Treatment 
Patients were treated with a combined approach including surgery, radiotherapy, and 
chemotherapy. Overall, 358 patients underwent tumor resection at the time of diagnosis 
or after chemotherapy (313 children and 45 adolescents). Surgery was complete in 45% 
and 44.4% of cases, respectively. The high rate of complete resections performed at the 
time of diagnosis (IRS group I) among the adolescents is explained by a large number 
of patients with paratesticular tumors in this age group. 
Data regarding radiotherapy were available for 598 patients. The percentage of patients 
treated with radiation was similar in the 2 age groups (61.6% in children and 59.4% in 
adolescents). There were no differences with regard to the doses administered, with the 
median dosage being 44.8 gray (Gy) (range, 14.4-69.0 Gy) for children and adolescents 
alike. 
The response to initial chemotherapy was evaluable in 438 patients and was good (CR + 
PR) in 74.3% of children and 81.1% of adolescents. Adolescents had a higher, although 
not statistically significant (P = .4), rate of tumor progression during the course of 
treatment (5.4% vs 2.9% in children). 
 
 13 
 
Survival 
With a median follow-up of 8.8 years (range, 3 years-20.5 years), the 5-year OS rate 
was 68.9% for children and 57.2% for adolescents (P = 0.006), and the 5-year PFS rate 
was 64.3% and 48.1%, respectively (P = .02) (Fig. 1). 
 
Table 1. Clinical Characteristics of the Patients 
Characteristic 
Sex 
Children 
(N 5 
567) 
% Adolescent
s (N 5 76) 
% Total 
(N 5 643) 
Male 337 5
9
.
4 
53 6
9
.
7 
390 
Female 230 4
0
.
6 
23 3
0
.
3 
253 
Primary site      
Orbit 56 9
.
9 
2 2
.
6 
58 
Head and neck 57 1
0
.
1 
9 1
1
.
8 
66 
Parameningeal 106 1
8
.
7 
10 1
3
.
2 
116 
GU BP 57 1
0
.
1 
5 
.
6 
62 
GU NON-BP 73 1
2
.
9 
28 3
6
.
8 
101 
Extremities 84 1
4
.
8 
9 1
1
.
8 
93 
Other sites 134 2
3
.
6 
13 1
7
.
1 
147 
Histology      
Alveolar 185 3
2
.
6 
36 4
7
.
4 
221 
Non alveolar 374 6
.
0 
39 5
.
3 
413 
NOS 8 1
.
4 
1 1
.
3 
9 
T 
classification 
     
T1 262 4
6
.
2 
36 4
7
.
4 
298 
T2 296 5
2
.
2 
36 4
7
.
4 
332 
Missing 9 1
.
6 
4 5
.
3 
13 
N 
classification 
     
N0 405 7
1
.
4 
42 5
5
.
3 
447 
N1 123 2
1
.
7 
27 
5
.
5 
150 
Missing 39 6
.
9 
7 9
.
2 
46 
Tumor size 
cm 
     
<5 243 4
2
.
9 
32 4
2
.
1 
275 
>5 305 5
3
.
8 
39 5
1
.
3 
344 
Missing 19 3
.
3 
5 6
.
6 
24 
IRS group      
I 65 1
1
.
5 
20 2
6
.
3 
85 
II 72 1
2
.
7 
7 9
.
2 
79 
III 329 5
8
.
0 
25 3
2
.
9 
354 
IV 101 1
7
.
8 
23 3
0
.
3 
124 
Missing —  1 1
.
3 
1 
 
Abbreviations: GU BP, genitourinary bladder/prostate; GU NON-BP, genitourinary non-
bladder/prostate; IRS, Intergroup Rhabdomyosarcoma Study; NOS, not otherwise specified. 
 
When patients with localized disease were considered alone, the results were similar in 
children and adolescents, with 5-year OS rates of 76.6% versus 78.6% and 5-year PFS 
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rates of 72.5% versus 66.8%, respectively (P: 0.9162). Patients with metastatic disease 
at the time of diagnosis fared much worse, with the OS and PFS rates dropping to 
31.8% and 24.6%, respectively, for children, and 10.4% and 5.8%, respectively, for 
adolescents (P: 0.01). 
Multivariate analysis identified several factors that were independently and significantly 
correlated with better survival: age < 15 years, favorable tumor sites, and no lymph 
node or metastatic dissemination (Table 2). All these variables also were confirmed to 
be independent prognostic factors for PFS. 
Because previous studies found age to be significant using 1 year and 10 years of age as 
the lower and upper cutoff values, we performed a further analysis for these 2 age 
groups. The survival rate was much the same in children ages 10 years to 14 years and 
adolescents, and was worse than in younger children (Fig. 2). The 5-year OS and PFS 
rates were significantly higher in children ages 1 year to 9 years compared with children 
ages 10 years to 19 years: 72% versus 56.8%, respectively, (P < .0001) and 64% versus 
52%, respectively (P: 0.003). 
A new multivariate analysis in which different age groups were taken into account (age 
< 1 year, ages 1year-9 years, and ages 10 years-19 years) produced similar results, with 
age (1 year-9 years), favorable tumor sites, and the absence of lymph node or metastatic 
dissemination found to be independently associated with better OS and PFS. 
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Figure 1. (Top) Overall survival and (Bottom) progression free survival are shown in children 
and adolescents with rhabdomyosarcoma. 95% CI indicates 95% confidence interval. 
 
 
DISCUSSION 
 
Despite several reports suggesting that the survival trends for adolescents with cancer 
are not improving to the same degree as in children (4,5), to our knowledge there have 
still been few studies published to date regarding this particular population, and none 
focusing on RMS. 
The STSC protocols did not differentiate treatment by age; in particular, there were no 
differences with regard to the local treatment strategies and similar percentages of 
children and adolescents underwent surgery and radiotherapy. 
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In our analysis, the survival results were better for children. Various reasons have been 
suggested to explain why adolescents may fare less well than children with the same 
disease, and one of the most important may be a higher incidence of adverse prognostic 
factors in older patients. Our data confirm this aspect in patients with RMS; unfavorable 
tumor characteristics (eg, alveolar subtype, lymph node involvement, and metastases at 
the time of diagnosis) were more common in adolescents than in children. An 
unexpectedly high number of adolescents with paratesticular tumors were registered in 
the STSC protocols, possibly reflecting a more effective referral to AIEOP centers by 
urologists and surgeons. The paratesticular site is highly favorable and explains why 
adolescents had a higher percentage of complete tumor resections at the time of 
diagnosis; this may also have contributed to raising the PFS and OS in the adolescent 
age group. 
Age per se has been indicated as a prognostic factor in various tumors, including RMS 
(11,12). Joshi et al analyzed the clinical features and treatment outcome of patients aged 
< 21 years in the IRS group protocols and concluded that a larger percentage of patients 
aged > 10 years have an alveolar histology, unfavorable tumor sites, and a more 
advanced tumor stage than noted in children aged < 10 years, but all these features were 
not enough to justify their worse outcome, and age remained a strong independent risk 
factor (2). More recently, age (> 10 years and < 1 year) proved to be an adverse 
prognostic factor in a pooled analysis of 788 patients with metastatic RMS (3). In the 
current study, which included patients with localized and metastatic RMS, unfavorable 
tumor features and advanced stage in particular appeared to have a more important role, 
with the role of age diminishing only when localized tumor was considered separately. 
The outcome was very similar for the patients ages 10 years to 14 years and those ages 
14 years to 19 years, suggesting that the age cutoff of 10 years may be more appropriate 
for the purpose of attributing different risk factors. The results of the current study thus 
indicate that adolescents should not be treated differently from younger children on the 
basis of age alone. 
Some authors have suggested that drug metabolism or treatment-related toxicity might 
differ between adolescent and younger patients, potentially explaining the difference in 
outcome (13). The limited number of major toxic events recorded in the population 
analyzed in the current study prevented us from investigating this aspect. 
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Table 2. Five-Year Overall Survival by Prognostic Factor (Multivariate Analysis) 
 
 
Abbreviations: 95% CI, 95% confidence interval; HR, hazard ratio; IRS, Intergroup 
Rhabdomyosarcoma Study. a Reference category. 
  
Factor Patients Events 
HR (95% 
CI) 
P 
Age, y 567 187 1a .0146 
 
76 36 
1.67 (1.11-
2.52) 
 
Tumor site 225 38 1a .0007 
 
418 185 
1.98 (1.33-
2.93) 
 
Lymph node 
involvement 
447 109 1a <.0001 
 
150 91 
1.95 (1.41-
2.69) 
 
IRS group 85 3 1a <.0001 
 
79 18 
5.39 (1.56-
18.59) 
 
 
354 114 
6.37 (1.96-
20.74) 
 
 
124 87 
17.10 
(5.08-
57.52) 
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Figure 2. Progression-free survival is shown by age group. 95% CI indicates 95% confidence 
interval. 
 
However, it is important to improve our knowledge in this area by planning clinical 
pharmacology studies in these patients. 
Another particular factor that is apparent in the adolescent population is the diagnostic 
delay. Several authors have suggested that the time elapsing from the onset of 
symptoms to diagnosis is longer for adolescents than for children (6,14). This was 
confirmed in the population in the current study, in whom the median diagnostic delay 
for adolescents was nearly twice as long as that for children (8.4 weeks vs 4.8 weeks), 
and suggests that the more advanced stage of disease noted in adolescents, and the 
consequently worse prognosis, may be partially explained by a late diagnosis. The 
reasons for this diagnostic delay lie within the limited awareness of families and the 
community that adolescents can develop cancer and in the fact that adolescents tend to 
have a strong sense of independence and may be reluctant to ask for help or submit to a 
medical examination, and therefore symptoms are often attributed to physical exertion, 
fatigue, trauma, and stress. 
An important issue that most likely interferes with any improvement being made in the 
survival of adolescents concerns their limited participation in clinical trials (5,15). 
When survival rates and accrual rates were compared using Surveillance, 
Epidemiology, and End Results (SEER) data, an overlap became apparent: the lower the 
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accrual rate, the worse the results in terms of survival (16). To our knowledge, the 
protocols coordinated by the STSC were the only national multicenter protocols avail-
able for children with RMS in Italy, and should be considered a type of standard of 
treatment. Only 27% of the expected number of adolescents was recruited into the 
STSC protocols, however, whereas > 90% of the expected numbers of children were 
enrolled in these protocols during the same period. This poor recruitment of adolescents 
in pediatric protocols has been highlighted by a recent analysis comparing the number 
of cases registered at the AIEOP centers with the incidence rates obtained from the 
AIRTUM population-based registries by cancer type. The O/E ratio for RMS was 0.33, 
which is one of the highest among all cancer types in adolescents but grossly unsatis-
factory (10). This demonstrates that adolescents in Italy are often referred to adult 
oncology units although their disease is a “pediatric” cancer. Programs dedicated to 
adolescents and young adults are still limited and adolescents with RMS may 
consequently receive treatment according not to current pediatric guidelines but to the 
approach adopted for adult soft tissue sarcoma, which may make their survival rates less 
satisfactory, as shown by the analysis of a series of adult patients with RMS (17). 
 
CONCLUSIONS 
 
The survival of children and adolescents enrolled in STSC protocols could be 
considered to be satisfactory, especially in patients without metastases. The results of 
the current study indicate that RMS presents with more aggressive features in 
adolescents and this has a major impact on their survival. An additional factor concerns 
the finding that only a small percentage of the adolescents affected are enrolled in 
clinical trials, and this may prevent them from receiving the best possible care. A better 
cooperation with oncologists who treat adults is mandatory to improve the treatment of 
adolescents with RMS. 
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2 ANALISI DATI TOPOTECAN/CARBOPLATINO 
 
2.1 Introduzione 
 
Il RMS è il più comune sarcoma delle parti molli nella popolazione pediatrica e 
adolescente; nelle ultime decadi l’affinamento dell’approccio multimodale alla 
patologia, costituito da chirurgia, radioterapia (RT) e polichemioterapia (CT), ha 
permesso di migliorare moltissimo la prognosi dei pazienti pediatrici affetti da questa 
neoplasia, passando da una sopravvivenza a 5 anni del 50% negli anni ’70 al 70% degli 
anni ’90 (1). Circa il 90% dei pazienti con malattia localizzata all’esordio ottiene una 
remissione completa; tuttavia 1/3 di pazienti ricade (2, 3). Per questi pazienti 
(metastatici, refrattari, recidivi), la prognosi è ancora ad oggi infausta (4). 
Sono quindi necessari nuovi farmaci e nuove strategie terapeutiche per migliorarne la 
prognosi. 
Risulta di fondamentale importanza identificare fattori prognostici utili a disegnare 
protocolli “risk-based”. Un recente studio ha dimostrato che l’istologia, la sede, il tipo e 
il timing della recidiva sono fattori correlati alla prognosi in modo significativo (5).   
Tra i vari farmaci identificati come attivi in studi preclinici e di fase I vi sono i derivati 
delle Camptotecine, Irinotecan e Topotecan. Si tratta di molecole che inibendo la 
Topoisomerasi I interferiscono con la divisione cellulare e la replicazione del DNA. 
Entrambe le molecole hanno dimostrato in studi preclinici attività su linee cellulari di 
numerosi tumori pediatrici, un buon profilo di tossicità nonché efficacia in studi di fase 
I (6, 7, 8, 9), anche sui RMS (10, 11). 
Vista l’attività delle singole molecole, successivamente sono state studiate varie 
combinazioni: Topotecan+ciclofosfamide (12, 13), Topotecan alternato allo schema 
VAC (14), Topotecan+Vincristina e Doxorubicina (15, 16)  
Da tali studi emerge che questi farmaci, pur non impattando in modo eclatante sulla 
sopravvivenza, permettono di ottenere un discreto tasso di riposta in pazienti spesso 
pesantemente pretrattati; vengono quindi attualmente considerati delle opzioni 
terapeutiche potenzialmente valide.  
L’attuale Protocollo per il trattamento del RMS (EpSSG 2005) propone in seconda linea 
una strategia terapeutica basata su un regime con Topotecan e Carboplatino. Pazienti 
che non rispondono in maniera soddisfacente ai primi 3 cicli di CT dimostrano una 
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cattiva prognosi e sono considerati “refrattari”; pertanto vengono shiftati ad un 
trattamento che prevede l’utilizzo di farmaci non utilizzati fino ad allora (Topotecan, 
Carboplatino, Ciclofosfamide ed Etoposide; l’antraciclina viene utilizzata nei pazienti in 
cui non era prevista in prima linea). Stesso dicasi per i pazienti che ricadono dopo il 
termine della CT di prima linea. 
Del Topotecan si è detto sopra; il razionale per l’utilizzo del Carboplatino in questo 
setting si basa sul precedente impiego dello stesso in regimi polichemioterapici 
riconosciuti attivi nel RMS quali il CEVAIE. Carboplatino è stato poi usato da solo in 
un “window study” dal UKCCSG nonchè in uno del CWS per i RMS metastatici. La 
fattibilità della combinazione è stata provata in occasione di uno studio di fase II 
eseguito al Bambin Gesu’ di Roma. 
Un’analisi preliminare dei risultati ottenuti nei pazienti affetti da RMS recidivo o 
refrattario trattati con Topotecan e Carboplatino, ha confermato la fattibilità della 
combinazione: la tossicità è risultata lieve  e prevalentemente ematologica;  il tasso di 
risposta discreto, comparabile con quello osservato con altre combinazioni. 
Su tale base è stato condotto uno studio prospettico multicentrico su pazienti affetti da 
RMS refrattario/recidivo trattati in seconda linea con il regime Topotecan/Carboplatino. 
Lo scopo dello studio era analizzare le caratteristiche delle recidive, il profilo di 
tossicità e l’efficacia della combinazione Topotecan/Carboplatino. 
 
Segue l’articolo che a breve sarà sottomesso a rivista scientifica. 
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2.2 A Topotecan/Carboplatin based strategy for children with 
refractory or recurrent rhabdomyosarcoma 
 
Alessia Compostella, MD1, Gianni Bisogno, MD, PhD1 et al.  
 
ABSTRACT 
The prognosis for children with resistant/relapsing Rhabdomyosarcoma (RMS) remains 
poor and therefore there is a need to test new drugs combinations. Topotecan (T) and 
Carboplatin (C) are known to have activity against a variety of pediatric tumors so a 
T/C based chemotherapy has been proposed as second line chemotherapy for children 
relapsed after being treated in the soft tissue sarcoma committee (STSC) protocols.  
Methods:  
38 patients with available data on response have been analyzed: 8 resistant to first line 
treatment and 30 treated at relapse. Treatment: T: 2 mg/m2 days 1,2,3; C: 250 mg/m2 
days 4,5 every 3 weeks. Tumor response has been evaluated after 2 cycles adopting 
standard criteria: complete response (CR); partial response (PR= tumor size reduction 
>50%); minor response (MR= reduction <50%); no response (NR= reduction <25%), 
progressive disease (PD= increase of tumor size or detection of new lesions) 
Results: 
18 patients presented unfavorable histotype and 19 a favorable one (1 NOS). At 
diagnosis IRS Group was: II: 3 patient; III: 25; IV: 10. Tumor site was unfavorable in 
the great majority of children (30/38): 9 parameningeal (PM), 9 extremities, 9 other 
sites, 3 genitorurinary bladder-prostate (GU-BP); among 8 favorable sites 4 were head 
and neck non parameningeal, 3 genito-urinary non BP, only 1 orbit. 24 patients received 
2 cycles, 3 only 1 due to early PD. Toxicity was predominantly hematologic with no 
severe non-hematologic toxic events reported. Major response was evident in 9 patients 
(CR+PR). The response rate was globally 28%; 15% in favorable histology and 33% in 
unfavorable one. 
Conclusions: 
Our study shows that the T/C combination has a mild toxicity in pretreated patients. The 
response rate is somewhat lower when compared to other combinations tested in phase 
II studies but it is of interest for the population with alveolar subtype. 
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INTRODUCTION 
 
Despite the success of current multimodal therapy which has increased the survival of 
patients with RMS over 70% there is still a substantial number of patients who relapse 
and need effective salvage chemotherapy. Thus it is important to investigate novel 
antineoplastic combinations for their potential incorporation into front line therapy. 
In this study we tested a chemotherapy strategy based on the administration of regimens 
including Topotecan (T) and Carboplatin (C) in a group of children and adolescents 
with refractory RMS. 
Topotecan, a campthotecine derivative, has demonstrated in pre-clinical studies high 
activity against pediatric malignancies such as medulloblastoma, neuroblastoma and 
rhabdomyosarcoma. Consequently several studies of T alone or in association with 
other antiblastic drugs were initiated. 
Carboplatin has been part of previously used regimens (CEVAIE) that proved to be 
effective against RMS (1). It has also been used alone in a window study conducted by 
the UKCCSG. A phase II trial has been performed at the Bambino Gesù Hospital in 
Rome showing the feasibility of the proposed regimen. The T/C combination is also 
used as window treatment in the current CWS protocol for metastatic RMS. 
This two drugs have constituted the base of the second line strategy recommended for 
children with RMS who relapsed after being treated in the STSC protocols. 
 
MATERIAL AND METHODS 
 
Between 2002 (only one patient was diagnosed in 1995) and 2011, 38 patients under 19 
years old joined this study. They were registered from 12 centers belonging to the 
AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) and taking part in 
studies coordinated by the AIEOP STSC.  
Eligible patients were required to have a histologically-confirmed diagnosis of RMS, 
and to be refractory or relapsing after the inclusion in one of the protocols coordinated 
by the STSC. 
Other eligibility criteria were: a life expectancy of at least 8 weeks, a modified Lansky 
score of > 50, recovery from the toxic effects of prior chemotherapy, a hemoglobin 
level greater than 9 g/dl, an absolute neutrophil count greater than 1,500/mm3, a platelet 
count higher than 100,000/mm3, adequate liver function (bilirubin level ≤ 1.5 mg/100 
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ml; ALT ≤ twice the normal value), adequate renal function (serum creatinine 
concentration ≤ 1.5 mg/dL or creatinine clearance > 60 ml/min/1.73 m2) and normal 
metabolic parameters (serum electrolytes, glucose, calcium, phosphorus). Patients with 
an interval of less than 3 weeks since the administration of radiotherapy or 
chemotherapy were excluded. 
At the baseline, the tumor was reassessed, with computed tomography (CT) or a 
magnetic resonance imaging (MRI) scans of disease sites and measurements of all 
disease parameters, chest X-ray, chest CT scan, whole body technetium bone scan and 
bone marrow aspirates and biopsies.  
The study was approved by the Ethics Committees of each center taking part and 
informed consent was obtained from patients or parents, as appropriate. 
 
Treatment 
Patients received 2 blocks of T\C, followed by alternating blocks of Topotecan \ 
Cyclophosphamide and Carboplatin \ Etoposide for a total of 6 courses with 3-week 
interval (see figure 1).  
Local treatment was scheduled after the two initial courses. Surgery and radiotherapy 
had to be considered but the type and time of local treatment were left to the responsible 
clinician according to the patient condition, relapsing tumor characteristics, and 
previous treatment. The coordinating STSC Centre was available to discuss the strategy 
for the most difficult cases.  
The schedule for drugs administration is described in figure 1 and was as follow: 
Topotecan: 2 mg/m2/day administered by 30 minutes intravenous infusion once daily 
on day 1, 2 and 3 (total dose 6 mg/m2/course); Carboplatin: 250 mg/m2/day in 1 hour 
intravenous infusion on day 4 and 5 (total dose 500 mg/m2 course). 
Cycles were given every 21 days, with neutrophils >1.0 x 109/l and platelets to >80 x 
109/l and following resolution of non-hematopoietic toxicity. Use of colony-stimulating 
factors were given according to Institutional policy. 
Toxicity was graded using the National Cancer Institute Common Toxicity Criteria 
version 2.0. 
 
Response evaluation 
After the initial two T/C courses and at the end of treatment, a formal assessment of the 
primary tumor and all sites of metastases had to be performed.  
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Response criteria were as follows: complete response (CR) = resolution of all evidence 
of disease; partial response (PR) = a tumor size reduction of more than 50% in the sum 
of the products of the two maximum perpendicular diameters of all measurable lesions; 
minor response (MR) = a reduction of less than 50% but more than 25% in the sum of 
the products of the two maximum perpendicular diameters of all measurable lesions. 
Stable disease or a reduction in size of less than 25% was recorded as no response (NR), 
while an increase in tumor size or the detection of new lesions was considered as 
progressive disease (PD). Responses had to last at least 4 weeks after the assessment of 
the response.  
Due to the difficulty in judging tumor response on bone marrow aspirates, we decided 
not to consider the bone marrow in the assessment of tumor response unless there was 
clear evidence of progressive disease or a new lesion.  
 
Statistical method 
Survival curves were calculated using the Kaplan-Meier method, considering: overall 
survival (OS), from the dates of relapse to latest follow-up or death from any cause; 
progression-free survival (PFS), from diagnosis to first progression, relapse, death from 
any cause or latest contact for children who never experienced an event.  
The log-rank test was used to compare survival rates between different subgroups of 
patients in univariate analysis, considering patients’ characteristics (age and gender) and 
tumor features (histological subtype, site, size, invasiveness, lymph node involvement, 
type and number of metastases). The different sites were grouped according their 
prognosis in favorable (orbit, head and neck, genitor-urinary non bladder prostate) and 
unfavorable (parameningeal, extremities, bladder-prostate, other sites). A p-value of less 
than 0.05 was considered statistically significant. A multivariate analysis was conducted 
using Cox’s proportional hazards regression method to determine the independent 
prognostic influence of pretreatment factors on survival, using the variables correlated 
with OS and PFS at univariate analysis.  
A phase II methodology using a Gehan 2-step design has been applied to evaluate the 
response to the two initial T/C cycles. The expected effectiveness ( ) was considered as 
20% for the whole group. If at least one response was recorded in the first 14 eligible 
patients, recruitment was to continue to at least 25 patients so that the standard error of 
the observed response rate would be 0.10.  
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The study was approved by the Ethics Committees of all centers taking part and 
informed consent was obtained for all patients enrolled on the protocol.  
 
 
RESULTS 
 
Clinical features 
A total of 38 patients joined the study, 32 of whom were evaluable for response to the 
T/C response study. Patients characteristics are shown in table 1. The age range was 0.4 
– 18.6 years (median 4.7; media 6.2). 16 were male, 22 were female. Histotypes were: 
18 were unfavorable RMS, 20 favorable (18 embrional RMS, 1 spindle cell RMS, 1 
NOS RMS). Tumors were mainly located in unfavorable sites. 10 patients were 
metastatic at diagnosis. At the entry in the study 8 patients had persistent disease at the 
end of first-line treatment, 20 had a loco-regional relapse (15 only local, 1 with 
concomitant lymph node involvement, 4 only node involvement ), the others had only 
distant relapse or local and distant relapse. 
 
Treatment 
Patients had been previously treated in 12 italian hemato-oncology units according to 
different protocols named RMS88, RMS4.99, RMS96, EpSSG2005. Surgery has been 
performed in all patients at diagnosis, nearly all (35) being diagnostic biopsies; 10 
patients underwent surgery after initial chemotherapy. Radiotherapy was delivered to 23 
patients during first line chemotherapy (CT); 15 did not (8 of them because of age). 
First line CT included high-dose chemotherapy with stem cell rescue in 2 patients.  
Local treatment was scheduled after the two initial T/C courses: 8 patients underwent 
surgery; 2 of them being microscopically radical, 3 macroscopically radical, a patient 
suffer a mutilating operation (exenteratio orbitae), 2 had no data about. Radiotherapy 
was delivered to 20 patients, 12 of them had been irradiated during first line 
chemotherapy, 8 were not (4 because of young age).  
After T/C CT many patients were treated with alternating Topotecan/Cyclofosphamide-
Etoposide/Carboplatin courses till progression. Other drugs frequently used were low 
dose Vinorelbine and Cyclophosphamide. Some patients have been treated with poliCT: 
VAC, ICE, Gemox; drugs less used were Irinotecan, Vincristine, Temozolamide, 
Caelix. A patients with recurrent RMS in the upper extremities underwent local 
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treatment with arterial Cisplatin. 2 patients were treated with high dose CT and 
autologous transplantation. 
 
Response and outcome 
6 patient were not evaluable for response to the two initial T/C cycles: local treatment 
(RT/surgery) was used at relapse before T/C administration in 4 patients; 2 other 
patients were not evaluated according established criteria for response to T/C CT. 
Overall in 32 evaluable patients, 2 CR and 7 PR were documented, for an overall 
response rate of 28%. A minor response was recorded in 3 cases. 11 were PD, 9 SD. 
When any type of tumor size reduction (complete, partial, minor) was considered, a 
37.5% response rate was calculated (12/32). 5 years OS was nearly 17%, 5 years PFS 
was 14%.  
Alveolar RMS seem to have a better response to the T/C regimen with 6/17 objective 
responses, then 35% (47% considering also MR: 8/17), rare stabilizations, a great 
number of progressions (8/17: 47%); favorable RMS showed 3/15 (20%) responses 
(26% considering MR); but many stable disease (8/15: 53%) and few progressions. 
Among 5 evaluable patients relapsed on therapy 5 had no response (neither a minor 1) 
and usually progressed to T/C. Among 24 evaluable patients who relapsed after 
completing CT, 9 had a good response to second line CT and 3 had a minor response.   
 
Toxicity 
Toxicity of T/C based chemotherapy was mainly haematological: 24 out of 38 patients 
experienced neutropenia or anemia or thrombocytopenia, some of them with 
concomitant fever. One patient experienced cytopenia and tubulopathy, one patient 
experienced cytopenia and mucositis, 1 suffered isolated nephrotoxicity. A heart disease 
was discovered in a child after receiving the combination. 6 out of 33 had no toxicity. 4 
patients had no data about chemotherapy toxicities. Overall 8 patients are currently 
alive; 30 are dead. 
 
DISCUSSION 
 
The treatment of patients with refractory RMS is still problematic and patients 
prognosis is still poor. It’s a habit to treat refractory patients with drugs not used during 
first line treatment in attempt to overcome drug resistance. Campthotecin derivatives are 
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anticancer agents that inhibit Topoisomerase I activity; among of them are Irinotecan 
and Topotecan; both have shown promising results in preclinical studies on human 
tumor xenografts derived from pediatric tumors such as RMS and medulloblastoma 
(MDB) (2, 3, 4). Phase I clinical trials confirmed the preclinical findings both in adults 
(5, 6) and children (7, 8, 9). Phase II studies in children confirmed the achieved 
improvement in neuroblastoma and RMS (10, 11, 12). Carboplatin has known activity 
against a variety of pediatric solid tumors, either alone or in combination therapy, and is 
less toxic than Cisplatin (CDDP) and than most other agents. The use of T after a DNA 
damaging agents such as Carboplatin is appealing in that T may prevent repair of 
Carboplatin-induced damage (13). For the above reasons, T and C seemed a rational 
combination for clinical exploration in pediatric malignancies.  
As a consequence we designed a T/C based protocol for patients relapsing after been 
treated in one of the STSC protocols. As a first step we analyzed tumor and patients 
characteristics to find out factors important in determining the first and second line 
treatment response rate. Previous studies found that tumor histology, tumor primary 
site, type of recurrence and temporal relation to therapy were associated significantly 
with prognosis in patients with recurrent RMS (14). In fact OS of patients who suffers 
distant relapse differs dramatically from who suffer only local recurrence (15). The 
timing of recurrence also influence prognosis. OS for patients whose disease recurred 
on therapy was significantly lower than patients with late failures (14). Similar results 
were published by IRSG and CWS were the prognosis of relapsed patients was 
significantly different between patients who developed recurrence after completing CT 
compared with patients who had developed recurrence while receiving CT (19% vs. 
2,7% P<0,05) (16). Our data do not permit to calculate time of recurrence but we can 
say that patients whose disease progressed soon during first line CT or did not show a 
good response to first courses showed no response even to second line CT and 
discouraging outcome.  
In our study IRS stage seems to affect prognosis (statistical significance for OS, a trend 
was evident for PFS). Furthermore, primary site seem to be linked to response rate. In 
fact, 7 out of 8 patients with no response to first line CT were located in an unfavorable 
primary site (4 of them were PM). We found the same data in non-responders to second 
line CT: the primary site of the tumor was unfavorable in 18 out of 20 patients who did 
not show any sensitivity to T/C regimen. 
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About treatment of relapsed patients, to date few phase II trials have been performed; in 
most of the studies the total evaluable population was small (often <20 patients) and 
heterogenous (MDB, osteosarcomas, PNET, RMS…). Our series included only patients 
with RMS; 32 patients out of 38 were evaluable for response; an overall response rate 
(ORR) of 28% has been obtained with a 3 years progression free survival (PFS) of 17% 
and a 3 years overall survival (OS) of 24%. This results seem not so satisfactory; but it 
has to be taken into account the poor prognosis of these heavily pretreated patients and 
the limited success obtained with many other drugs in the same setting. Drugs 
belonging to adult oncology like Oxaliplatin, Gemcitabine, 5 Fluorouracil, Taxanes, 
showed very limited activity in pediatric solid tumors (17, 18). Interesting comparison 
could be done with Vinorelbine and Irinotecan. In fact both these molecules, alone as 
well as administered with other drugs, demonstrated encouraging results; Vinorelbine 
(VNB) is a vinca alkaloid agent with a well known tolerability profile and activity in 
pediatric solid tumors; some studies assessed efficacy and tolerability of combination of 
VNB and Cyclophosphamide (19); this combination yielded a ORR 34-36% and a 
median survival time of 9 months (20). Irinotecan showed a ORR of 23% in a study 
with a protracted schedule (21); a ORR of 31,5% and a 3 y PFS of 15% were obtained 
when combined with VCR (randomized phase II window trial by COG) (22). The 
combination Irinotecan, VCR and Temozolomide (TMZ) has been tested in a phase I 
trial (23); a very good antitumor activity was obtained and based on these data the 
European Soft Tissue Sarcoma Group is evaluating a phase II trial to test a combination 
of Irinotecan with VCR +/- TMZ. A very good result has been obtained with the 
combination of Topotecan and Cyclophosphamide: 10/15 RMS showed an objective 
response (67% ORR) in the phase II by POG (24). 
According to the above mentioned data, the ORR obtained with Topotecan/Carboplatin 
is not so satisfactory but neither much worse than the results highlighted with some 
other combinations. Especially if we consider minor responses (MR) too we obtain a 
37,5% ORR; interestingly also a great number of stabilizations were observed (9/32: 
28%). Emerged an interesting difference in response rate between unfavorable RMS 
and favorable RMS: alveolar RMS seem to have a better response to the T/C regimen 
versus what observed in favorable RMS: 35% (47% considering MR too) versus 20% 
(26% with MR). Mascarenhas and Colleagues too found a higher RR by unfavorable 
RMS compared with favorable RMS, 48% versus <20%.  
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Toxicity of T/C based chemotherapy was mainly haematological and mild, usually 
reversible.  
At relapse to T/C based CT no “standard” treatment is known to be effective. Than a 
variety of strategies have been used in our series: RT and surgery if not performed 
before; metronomic CT (low dose VNB, Cyclophosphamide, Etoposide), high dose CT, 
Irinotecan, VAC, GEMOX  (Gemcitabine+Oxaliplatin) and so on. Because of this 
heterogeneity it is difficult to interpret data on OS in relation to T/C efficacy.  
We conclude that T/C based CT is very well tolerated with similar results in terms of 
RR. We consider it an option but these results are not so satisfactory. The rarity of the 
disease complicate the researchers work; an effort has to be done to enroll patients in 
clinical trials, eventually up to 21 years and join data and expertise. There is a strong 
need to individualize treatment (e.g. alveolar RMS good responder to T/C versus non 
alveolar?), to find out new molecular targets, new drugs or new schedules to improved 
prognosis of these young patients. 
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FIG 1: Treatment schedule
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TABLE 2 Tumor characteristics   
 
  
Sex  
- Male 16 
- Female  22 
Primary Site  
- Orbit 1 
- Head and Neck non Parameningeal 4 
- Head and ne ckParameningeal 9 
- Genito-Urinary Bladder Prostate 3 
- Genito-Urinary non Bladder Prostate 3 
- Extremities 9 
- Other sites 9 
Histology  
  Alveolar 18 
  Embrional  18 
  Spindle cell  1 
  Unknown 1 
T stage  
  T1 15 
  T2 22 
  Unknown  1 
N stage  
  N0 21 
  N1 16 
  Nx 1 
Tumor size  
  < 5 cm 12 
  > 5 cm 25 
  Unknown  1 
IRS group  
  I/II/III 28 
  IV 10 
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Overall Survival 
 
 
 
Overall Survival by IRS Group 
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Progression Free Survival 
 
 
 
Progression Free Survival by IRS Group 
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3 I NUOVI FARMACI 
 
3.1 Introduzione  
 
Negli ultimi anni il miglioramento delle tecniche di diagnostica, la ricerca in ambito 
farmacologico e l’approccio multimodale, hanno permesso un aumento della 
sopravvivenza dei bambini e adolescenti affetti da tumore. Mentre negli anni ’50 la 
quasi totalità dei casi esitava nel decesso, siamo giunti ora ad una sopravvivenza a 5 
anni del 75% (1). I maggiori successi sono stati ottenuti nell’ambito delle patologie 
ematologiche (leucemie e linfomi) mentre i risultati ottenuti nei tumori solidi sono stati 
meno eclatanti.  
La prognosi dei pazienti affetti da tumore dipende molto dallo stadio all’esordio: la 
sopravvivenza dei pazienti pediatrici affetti da rabdomiosarcoma (RMS) arriva, per 
esempio, al 70% quando la malattia è localizzata, ma scende al di sotto del 30% per i 
pazienti con malattia metastatica (2). La prognosi è particolarmente severa anche per i 
pazienti con malattia in recidiva e/o resistente al trattamento chemioterapico di prima 
linea. Risulta quindi di fondamentale importanza ricercare nuove strategie terapeutiche 
per i pazienti con malattia metastatica all’esordio o resistente al trattamento di prima 
linea. A tale scopo numerose sono le vie percorribili: lo studio di nuovi farmaci, di 
nuove schedule/combinazioni di farmaci noti, di formulazioni adatte alla 
somministrazione a pazienti pediatrici.  
L’ambito dei nuovi farmaci include sia le molecole/farmaci di ultima generazione che 
tanto hanno segnato la ricerca più recente (inibitori delle tirosin kinasi, anticorpi 
monoclonali), sia i farmaci non ancora utilizzati nel paziente pediatrico ma che ormai 
fanno parte del trattamento standard negli adulti.  
La ricerca ha via via identificato lo stretto legame esistente tra genetica e tumore. 
L’utilizzo di tecniche sempre più sofisticate di analisi ha permesso di studiare alcune 
delle basi molecolari del processo neoplastico e la ricerca sui farmaci antineoplastici si è 
recentemente focalizzata sulla cosiddetta “target therapy”. Le basi molecolari e le 
anomalie genetiche implicate nella malattia cancro, determinano uno squilibrio nella 
produzione/attivazione di alcune molecole. La determinazione della struttura delle 
molecole coinvolte ha permesso di “costruire” inibitori altamente selettivi in grado di 
interferire/bloccare i pathways cellulari erroneamente up/down regolati nel processo 
neoplastico. I successi ottenuti con alcune molecole hanno dato una spinta alla ricerca in 
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tale ambito: Imatinib, inibitore del recettore della tirosin-chinasi che blocca l’attività dei 
recettori c-Abl, c-Kit e PDGF, costituisce ad esempio uno dei più eclatanti successi 
della target therapy: il farmaco è divenuto rapidamente trattamento standard per i 
pazienti affetti da tumori gastrointestinali stromali e leucemia linfatica cronica. Dati 
preclinici promettenti riguardano anche molecole quali gli inibitori delle 
metalloproteinasi e gli inibitori di alcuni fattori di crescita quali VEGF, PDGF, EGF e 
dei loro recettori (3).  
Interferire con i pathways cellulari sregolati nella cellula neoplastica è sicuramente una 
via da percorrere. La ricerca deve pertanto perseguire tale obiettivo e gli studi clinici di 
fase I, II e III sulle “nuove molecole” sono uno strumento di fondamentale importanza, 
ancillare agli studi di laboratorio che ne costituiscono la base. Tuttavia, se l’inibizione 
di pathways coinvolti può essere una strategia efficace, non va sottostimato il fatto che 
vi sono molte alterazioni genetiche e più vie coinvolte in un tipo di tumore; molti 
processi biologici inoltre hanno vie “alternative” che possono potenzialmente bypassare 
il pathway con il quale il farmaco interferisce. Una spia di ciò è la non completa 
concordanza di risultati tra sperimentazione preclinica e clinica, soprattutto quando le 
molecole in studio vengono utilizzate da sole. Inoltre non vanno dimenticati i potenziali 
effetti collaterali dovuti ai molteplici ruoli che la molecola target può possedere e va 
considerata la possibilità dell’insorgenza di resistenze. Questo dimostra come 
probabilmente sia necessario pensare a dei “pannelli” di farmaci che mirino a bloccare i 
numerosi pathways coinvolti nel processo neoplastico. Tali premesse suggeriscono 
inoltre che la target therapy è una delle vie, ma non può essere la sola arma contro una 
patologia tanto complessa.  
E’ quindi importante non tralasciare le altre vie possibili: in particolare considerare 
schedule che prevedano la somministrazione di farmaci a bassi dosaggi ma in modo 
continuativo (“terapia metronomica”): risultati di studi recenti suggeriscono che la 
somministrazione di alcuni farmaci citotossici a basse dosi aumenta l’ effetto 
antiangiogenico dei farmaci. Tale approccio potrebbe essere utile per minimizzare la 
tossicità dei farmaci, soprattutto in pazienti che necessitano di trattamenti molto 
prolungati. I farmaci citotossici possono essere in quest’ottica associati alle nuove 
molecole, quali gli inibitori del VEGFR, per un reciproco potenziamento (4).  
Anche l’utilizzo di chemioterapici mutuati dall’esperienza nell’adulto dei quali esistano 
dati di efficacia su linee cellulari di tumori solidi pediatrici (es.: inibitori delle 
Topoisomerasi, Taxani…) è una via percorribile (5, 6). 
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Altra possibilità che si prospetta è lo studio della farmacologia di farmaci in uso in 
Oncologia Pediatrica (quali ad esempio le antracicline) volti ad ottimizzarne l’utilizzo 
(7). 
Da tali premesse emerge la complessità del problema e la molteplicità delle vie che 
vanno percorse. 
Le prospettive delineate rientrano nell’ottica di una visione “allargata” del problema: 
come sottolineato recentemente (8), la ricerca di nuovi agenti antitumorali è 
fondamentale e deve applicarsi su più fronti possibile, ma senza focalizzarsi su un’unica 
strategia. Le molecole di nuova generazione (target therapy) sono promettenti ma 
probabilmente non costituiranno, sole, la soluzione ad un problema tanto complesso. E’ 
necessario trovare le vie più adeguate per il miglior utilizzo dei farmaci nuovi e vecchi. 
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3.2 Trials clinici 
 
Il RMS è una neoplasia altamente chemiosensibile con ottimi tassi di risposta alla 
terapia di prima linea. Tuttavia i tassi di risposta e la prognosi di pazienti refrattari alla 
terapia di prima linea o che ricadono al termine della terapia di prima linea sono 
deludenti.  
La ricerca sui nuovi farmaci nell’ambito dell’Oncologia Pediatrica ha subito una 
notevole spinta negli ultimi anni proprio sulla base della necessità di migliorare la 
prognosi di questi pazienti. Le Aziende Farmaceutiche hanno manifestato un interesse 
crescente e chi lavora con la patologia neoplastica pediatrica sta iniziando a conoscere 
la complessità dell’iter che porta un farmaco dal laboratorio alla clinica passando per gli 
studi clinici di fase I, II, III. 
Gli studi clinici rendono possibile la raccolta di dati su tossicità, minima dose efficace, 
efficacia del farmaco testato da solo e in combinazione. Costituiscono il punto di 
passaggio obbligato e strettamente “controllato” per l’approvazione di un farmaco; per i 
pazienti la partecipazione a tali trials rappresenta una chance terapeutica; infatti si tratta 
di pazienti con patologia non più responsiva alla terapia standard, con poche prospettive 
terapeutiche (o nulle) e cattiva prognosi; hanno accesso attraverso i protocolli a “nuovi” 
farmaci potenzialmente efficaci (o più efficaci di altri) prima che questi siano sul 
mercato e godono di una supervisione specialistica particolarmente attenta e stretta; a 
tale proposito ricordo i dati già esposti in precedenza (capitolo 1) relativamente ai 
pazienti adolescenti/giovani adulti il cui scarso tasso di arruolamento nei trials clinici 
correla con la loro peggior prognosi (capitolo 1).  
Il Centro che partecipa al trial offre una chance terapeutica in più al paziente, può di 
conseguenza costituire “polo attrattivo”/di riferimento per altri centri minori a 
fallimento della terapia standard; per il Centro partecipare ad un trial clinico comporta 
la disponibilità di risorse e una adeguata expertise da parte del personale dedicato; a 
questo scopo da alcuni anni il nostro gruppo ha iniziato un percorso formativo 
nell’ambito dei trials clinici per figura medica, infermieristica e amministrativa (data 
manager). In tal modo è aumentata l’expertise necessaria e il Centro ha via via avviato 
la partecipazione a un numero sempre maggiore di protocolli di fase II e III nazionali e 
internazionali focalizzati prevalentemente su pazienti affetti da tumori solidi pediatrici 
refrattari/recidivi. Questo ha permesso al nostro Centro di diventare attualmente uno dei 
Centri Italiani con maggior offerta di trials clinici. 
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Partecipare alla ricerca su nuovi farmaci significa collaborare con numerosi partners in 
ricerca medica clinica, ricerca di base, aziende del settore del farmaco; per quanto 
concerne i tumori solidi pediatrici (in particolare i sarcomi delle parti molli), tra questi 
vi sono l’EpSSG (European Pediatric Soft Tissue Sarcoma Group), l’ ITCC (Innovative 
Therapies for Children with Cancer), Conticanet (CONNective TIssue CAncer 
NETwork), l’EMEA (European MEdicines Agency), ENCCA (European Network for 
Cancer Research in Children and Adolescents); l’obiettivo comune di tale 
collaborazione è trovare terapie innovative per la cura di pazienti pediatrici e 
adolescenti con sarcoma e uniformare le strategie dei centri europei per garantire 
standard di cura ottimali ai pazienti. 
Segue l’elenco dei trials a cui il Gruppo/Centro ha partecipato negli ultimi anni e sta 
partecipando, con lo stato dell’arte.  
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Indication of Trial Clinical 
Phase of 
Trial 
(I-IV) 
Year in which trial 
was conducted 
Open-Label trial of Glivec (imatinib mesylate) 
in patients with refractory desmoplastic small 
round cell tumors (DSRCT) expressing a 
molecular target of Glivec (PDGF-R and/or C-
kit) 
II Close 2010 
GEMOX: Studio di fase 2 con gemcitabina in 
combinazione con oxaliplatino nei tumori 
solidi pediatrici refrattari recidivati. 
II Close 2009 
BERNIE: Open-label, multi-center, 
randomized, two stage adaptive design study of 
the combination of bevacizumab with standard 
chemotherapy in minor patients with metastatic 
high risk rhabdomyosarcoma, non-
rhabdomyosarcoma soft-tissue sarcoma or high 
risk Ewing’s sarcoma/soft-tissue PNET 
II 2009- still open 
TOTEM 2: Phase 2-single arm studies of 
Temozolomide in combination with Topotecan 
refractory and relapsed neuroblastoma and 
other pediatric solid tumours 
II 2009- still open 
"Studio di fase III sull'efficacia 
dell'intensificazione della dose in pazienti con 
sarcoma di Ewing non metastatico 
(ISG/AIEOP EW1)" 
II 2010-still open 
Protocollo terapeutico con chemioterapia ad 
alte dosi, radioterapia, terapia di mantenimento 
con ciclofosfamide a basse dosi e anti-COX 2 
per sarcoma di Ewing metastatico: studio 
ISG/AIEOP (ISG/AIEOP EW-2)” 
II 2009-still open 
A Study to Determine the Activity of SCH 
717454 in Subjects With Osteosarcoma or 
II Close July 2010 
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Ewing’s Sarcoma That Has Relapsed After 
Standard Systemic Therapy (Protocol 
No. P04720) 
Phase II, open label, non-randomized study of 
second or third line treatment with sorafenib 
(BAY 43-9006) in patients affected by relapsed 
high-grade osteosarcoma. 
II 2009- still open 
A Phase 1/2 Combined Dose Ranging and 
Randomised, Open-label, Comparative Study 
of the Efficacy and Safety of Plerixafor 
(Mozaic) in Addition to Standard Regimens for 
Mobilisation of Haematopoietic Stem Cells 
into Peripheral Blood, and Subsequent 
Collection by Apheresis, Versus Standard 
Mobilisation Regimens Alone in Paediatric 
Patients, Aged 2 to <18 Years, with Solid 
Tumours Eligible for Autologous Transplants 
II 2010- still open 
Epoc-Doxo: Phase II pharmacokinetic study to 
assess the age dependency 
in the clearance of doxorubicin in paediatric 
patients with solid tumours and leukaemia 
II 2010- still open 
APREPITANT: MK0869-208  “A Phase III, 
Randomized, Double-Blind, Active 
Comparator-Controlled Clinical Trial, 
Conducted Under In-House Blinding 
Conditions, to Examine the Efficacy and Safety 
of Aprepitant for the Prevention of 
Chemotherapy-Induced Nausea and Vomiting 
(CINV) in Pediatric Patients” 
III 2011- still open 
HERBY: A phase II open-label, randomized, 
multi-centre comparative study of 
bevacizumab-based therapy in paediatric 
patients with newly diagnosed supratentorial 
high-grade glioma. 
II 2011- still open 
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PETIT2: A phase III,  two part, double-blind, 
randomized, placebo-controlled and open-label 
study to investigate the efficacy, safety and 
tolerability of eltrombopag, a thrombopoietin 
receptor agonist, in pediatric patients with 
previously treted chronic immune (idiopathic) 
thrombocytopenic purpura (ITP). 
III 2012 
VIT: International randomized phase II study 
of the combination of vincristine, and 
irinotecan with or without temozolomide in 
patients with refractory o relapsed 
rhabdomyosarcoma. 
II 2012- still open 
GIST: A Phase I/II study of Sunitinib in young 
patients with advanced gastrointestinal stromal 
tumor. 
I/II 2012 - still open 
MEPACT: Phase IV Surveillance study of 
patients with newly diagnosed high-grade, 
resectable non metastatic osteosarcoma to 
investigate the short-term safety profile of 
mifamurtide (MEPACT) as part of a combined 
chemotherapy treatment regime for this 
condition. 
IV 2012 - still open 
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3.3 Protocollo di fase II  
 
3.3.1 Introduzione 
Parte integrante del progetto era il raggiungimento di una adeguata expertise per la 
stesura di Protocolli di fase II-III. Tale obiettivo è stato raggiunto grazie alla formazione 
in itinere attraverso partecipazione a corsi specifici come:  
 “ITCC Training Days”, corso sullo sviluppo di nuovi farmaci in oncologia pediatrica, 
tenutosi a Roma dal 22 al 24 ottobre 2009.  
 “3rd ESO-SIOP Europe Masterclass in paediatric oncology”, tenutosi a Castelgandolfo, 
Roma, dal 12 al 18/06/2010. 
Inoltre la partecipazione attiva e via via crescente come subinvestigator a trials clinici di 
fase II e III, nazionali e internazionali, ha contribuito ad una progressiva conoscenza del 
percorso che porta alla stesura dei protocolli e della loro gestione; la formazione di un 
Gruppo dedicato ai “Nuovi Farmaci” è uno dei risultati di questo lavoro e costituisce 
senza dubbio un valore aggiunto per il Nostro Centro. 
Il gruppo è formato da: 
  Data Managers per la raccolta dati, la compilazione delle CRF (case reporting 
form) con supervisione medica, le relazioni con i centri coordinatori, i Monitors, le 
aziende sponsor, i comitati etici. 
  Infermiere di Ricerca dedicate a seguire i pazienti arruolati nei protocolli 
(contabilità e conservazione del farmaco,  preparazione e somministrazione della 
chemioterapia, relazione col paziente e i famigliari negli aspetti di loro competenza, 
feedback a medici e data managers). 
  Medici dedicati alla gestione superspecialistica dei pazienti in protocollo, con 
valutazione dell’eligibilità dei pazienti al protocollo, arruolamento degli stessi, 
consegna, spiegazione, firma dei consensi, prescrizione della chemioterapia, controllo e 
gestione degli eventi avversi (in particolare i “SAE”, serious adverse events), 
supervisione delle CRF. 
Il coinvolgimento come subinvestigator con la fondamentale partecipazione a 
Investigators’ Meeting (es: Windsor il 22-23.05.2008 per il Protocollo BO20924, 
Heathrow il 24.03.2009 per il Protocollo BO20924, Madrid il 19-20.01.2010 per il 
Protocollo BO20924) ed a visite di apertura del Centro ai protocolli, ha permesso 
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l’acquisizione di una certa expertise in questo ambito, frontiera relativamente “nuova” 
per il mondo pediatrico.  
A “conclusione” di tale iter formativo gli sforzi sono stati coordinati alla stesura di un 
protocollo di fase II per le recidive di tumori solidi pediatrici.  
L’oggetto del protocollo è il trattamento delle meningosi da RMS/EPNET con 
topotecan intratecale. La stesura del protocollo è in corso, la versione definitiva verrà 
probabilmente presentata alla riunione annuale sui tumori solidi pediatrici che si tiene a 
Padova verso la fine dell’anno.  
 
Segue quanto finora scritto del protocollo di fase II. 
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3.3.2 Phase II study of intrathecal topotecan in leptomeningeal 
relapsed rhabdomyosarcoma and Ewing PNET children and 
adolescents. 
 
SYNOPSIS 
Title Title:    Phase II study of intrathecal topotecan in leptomeningeal 
     relapsed rhabdomyosarcoma and Ewing PNET children 
     and adolescents.  
Principal Investigator Dr Gianni Bisogno 
Study centers   Hemato-oncology Department of Padua (coordinating 
     centre) 
     AIEOP centres/European hemato-oncology Hospitals 
Objectives    Primary: determine the therapeutic activity of IT  
     Topotecan in terms of Response rate and time to CNS 
     progression in pediatric patients with RMS/EPNET 
     tumors and leptomeningeal dissemination. 
     Secondary: assess duration of response, overall survival, 
     safety and toxicity 
Study design     Prospective non randomized phase II trial 
Number of patients  RMS: 
     EPNET:  
Inclusion criteria  Histologically confirmed RMS or Ewing PNET sarcoma 
     with leptomeningeal involvement (see assessment of 
     CNS dissemination). 
    CNS dissemination: positive CSF citology examination 
    or unequivocal evidence of leptomeningeal disease on 
    CT scan or MRI scan. 
    Patients < 21 years of age.  
    Patients, parents or legal representatives must provide 
     written informed consent. 
    Life expectancy of at least 8 weeks. 
    KPS > 60%.  
     Adequate organ function: 
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    Adequate haematological function: haemoglobin ³ 80 g/l,  
    neutrophil count ³ 1.0 x 109/L, platelet count ³ 100 x 109/L; in 
    case of bone marrow disease: neutrophils ³ 0.5 x 109/l and  
    platelets 75 x 109/l; 
    Adequate renal function: normal creatinine related to patient’s 
    age: 
    o 0 – 1 year: 40 μmol/L 
    o 1 – 15 years: 65 μmol/L 
    o 15 – 20 years: 110 μmol/L 
    Adequate hepatic function: bilirubin 1.5 x ULN; AST and  
   ALT 2.5 x ULN (AST, ALT 5xULN in case of liver metastases) 
    Wash-out of 3-4 weeks in case of prior chemotherapy. 
    Concurrent CT to control systemic disease is allowed if 
     the systemic CT is not a phase I agent that significantly 
     penetrates the CSF or an agent known to have serious 
     unpredictable CNS side effects. 
    Concurrent dexamethasone or prednisone allowed if part 
     of a systemic CT regimen. 
    At least 8 weeks since prior cranial irradiation and  
     recovered. 
    At least 14 days since prior investigational drug. 
    Fertile patients must use effective contraception. 
    Patient/family able to comply to the study protocol. 
 
Exclusion criteria  Clinical evidence of obstructive hydrocephalus.   
    Serious concomitant systemic disorders. 
    History of allergic reaction to study drug. 
    Pregnant or breast feeding mothers. 
    Concurrent whole brain or craniospinal irradiation. 
Treatments   Induction: Topotecan IT 0,4 mg/dose twice weekly for 6 
     weeks 
     Consolidation: Topotecan IT 0,4 mg/dose weekly for 4 
     weeks 
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     Maintenance: Topotecan IT 0,4 mg/dose twice monthly 
     for 4 months then monthly through year 1 
Assessment and  
Criteria for evaluation Efficacy: MRI/CT scans 
          CSF cytology (LP/intraventricular reservoir) 
    Safety:   Safety profile will be evaluated. Clinical and 
     laboratory toxicities/symptomatology will be graded 
     according to NCI-Common toxicity criteria AE v3.0. 
     The adverse events which are not reported in the NCI-
     Common toxicity criteria will be graded as mild,  
     moderate, severe, life-threatening 
Statistical method 
Post study follow up  Every 2 months up to death or study cut-off. 
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BACKGROUND 
 
Rhabdomyosarcoma/PNET 
 
Incidence and Epidemiology 
Childhood rhabdomyosarcoma, a soft tissue malignant tumor of mesenchymal origin, 
accounts for approximately 3.5% of the cases of cancer among children aged 0 to 14 
years and 2% of the cases among adolescents and young adults aged 15 to 19 years (2, 
3). The incidence is 4.5 per 1 million children and 50% of cases are seen in the first 
decade of life (4). Most cases of rhabdomyosarcoma occur sporadically, with no 
recognized predisposing factor or risk factor (8). Genetic conditions associated with 
rhabdomyosarcoma include Li-Fraumeni cancer susceptibility syndrome (with germline 
p53 mutations), (9, 10, 11) pleuropulmonary blastoma (with DICER1 mutations), (12, 
13) neurofibromatosis type I, (14) Costello syndrome (with germline HRAS mutations), 
(15-18) Beckwith-Wiedemann syndrome (with which Wilms tumor and hepatoblastoma 
are more commonly associated), (19, 20) and Noonan syndrome. (18, 21, 22)  
Dramatic improvements in survival have been achieved for children and adolescents 
with cancer (1). Between 1975 and 2002, childhood cancer mortality has decreased by 
more than 50%. For rhabdomyosarcoma, the 5-year survival rate has increased over the 
same time from 53% to 65% for children younger than 15 years and from 30% to 47% 
for adolescents aged 15 to 19 years (1).  
RMS may arise everywhere in the body. The most common primary sites for 
rhabdomyosarcoma are the head, the genitourinary tract, and the extremities (5, 6). 
Within extremity tumors, tumors of the hand and foot occur more often in older patients 
and have an alveolar histology; these tumors also have a higher rate of metastatic spread 
(7). Other less common primary sites include the trunk, chest wall, perineal/anal region, 
and abdomen including the retroperitoneum and biliary tract. Symptoms depend on the 
site of origin. 
 
Prognostic Factors 
The prognosis for a child or adolescent with rhabdomyosarcoma is related to the age of 
the patient, site of origin, tumor size (widest diameter), resectability, presence of 
metastases, number of metastatic sites or tissues involved, presence or absence of 
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regional lymph node involvement, histopathologic subtype (alveolar vs. embryonal), 
and delivery of radiation therapy in selected cases (5, 6, 23-30) as well as unique 
biological characteristics of rhabdomyosarcoma tumor cells (31). It is unclear whether 
response to induction chemotherapy, as judged by anatomic imaging, correlates with the 
likelihood of survival in patients with rhabdomyosarcoma, as one study found an 
association and another study did not (32, 33).  
Rhabdomyosarcoma is usually curable in most children with localized disease who 
receive combined-modality therapy, with more than 70% surviving 5 years after 
diagnosis (5, 6, 34). Local relapses are more frequent than metastatic ones. Relapses are 
uncommon after 5 years of disease-free survival, with a 9% late-event rate at 10 years. 
Relapses, however, are more common for patients who have gross residual disease in 
unfavorable sites following initial surgery and those who have metastatic disease at 
diagnosis (35). 
 
Cellular and molecular classification 
Rhabdomyosarcoma can be divided into several histologic subsets: embryonal 
rhabdomyosarcoma, which has embryonal, botryoid, and spindle cell subtypes; alveolar 
rhabdomyosarcoma; and pleomorphic rhabdomyosarcoma (36,37). 
Embryonal Rhabdomyosarcoma: the embryonal subtype is the most frequently observed 
subtype in children, accounting for approximately 60% to 70% of rhabdomyosarcomas 
of childhood (36).Tumors with embryonal histology typically arise in the head and neck 
region or in the genitourinary tract, although they may occur at any primary site. 
Embryonal tumors often show loss of specific genomic material from the short arm of 
chromosome 11 (44,45, 46). The consistent loss of genomic material at the chromosome 
11p15 region in embryonal tumors suggests the presence of a tumor suppressor gene, 
although no such gene has yet been identified. 
Botryoid and spindle cell subtypes: botryoid tumors represent about 10% of all 
rhabdomyosarcoma cases and are embryonal tumors that arise under the mucosal 
surface of body orifices such as the vagina, bladder, nasopharynx, and biliary tract.  
The spindle cell variant of embryonal rhabdomyosarcoma is most frequently observed 
at the paratesticular site (38). Both the botryoid and the spindle cell subtypes are 
associated with very favorable outcomes (37). 
 64 
 
Alveolar Rhabdomyosarcoma: approximately 20% of children with rhabdomyosarcoma 
have the alveolar subtype. An increased frequency of this subtype is noted in 
adolescents and in patients with primary sites involving the extremities, trunk, and 
perineum/perianal region (36).  
Unique translocations between the FOXO1 (previously called FKHR) gene on 
chromosome 13 and either the PAX3 gene on chromosome 2 (t(2;13)(q35;q14)) or the 
PAX7 gene on chromosome 1 (t(1;13)(p36;q14)) are found in 70% to 80% of patients 
with alveolar histology tumors (42, 43, 44). Translocations involving the PAX3 gene 
occur in approximately 59% of alveolar rhabdomyosarcoma cases, while the PAX7 
gene appears to be involved in about 19% of cases (42). 
Pleomorphic (Anaplastic) Rhabdomyosarcoma: pleomorphic rhabdomyosarcoma occurs 
predominantly in adults aged 30 to 50 years and is rarely seen in children (39). In 
adults, pleomorphic rhabdomyosarcoma is associated with a worse prognosis. In 
children, the term anaplasia is preferred (40). In a retrospective review of 546 pediatric 
patients, the presence of anaplasia was only associated in univariate analysis with 
inferior clinical outcome in patients with intermediate-risk rhabdomyosarcoma (41). 
 
Stage Information 
Before a biopsy of a suspected tumor mass is performed, imaging studies of the mass 
and baseline laboratory studies should be obtained. After the diagnosis of 
rhabdomyosarcoma has been made, an extensive evaluation to determine the extent of 
the disease should be done prior to instituting therapy. This evaluation should include a 
chest x-ray, computed tomography (CT) scan of the chest, bilateral bone marrow 
aspirates and biopsies, bone scan, magnetic resonance imaging (MRI) of the base of the 
skull and brain (for parameningeal primary tumors only), and CT scan of the abdomen 
and pelvis (for lower extremity or genitourinary primary tumors). 
A CT or MRI scan of regional lymph nodes should be considered. Abnormal-appearing 
lymph nodes should be biopsied when possible. One study has demonstrated that 
sentinel lymph node biopsies can be safely performed in children with 
rhabdomyosarcoma, and tumor-positive biopsies may alter the treatment plan (47). 
Positron emission tomography (PET) with fluorine-18-fluorodeoxyglucose (FDG) scans 
can identify areas of possible metastatic disease not seen by other imaging modalities 
(48-50). However, the efficacy of these two procedures for identifying involved lymph 
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nodes or other sites is currently under investigation, and these procedures are not 
required by current treatment protocols.  
As noted previously, prognosis for children with rhabdomyosarcoma depends 
predominantly on the primary site, tumor size, Group, and histologic subtype. Favorable 
prognostic groups were identified in previous Intergroup Rhabdomyosarcoma Study 
Group (IRSG) studies, and treatment plans were designed on the basis of assignment of 
patients to different treatment groups according to prognosis. Several years ago, the 
IRSG merged with the National Wilms Tumor Study Group and two large cooperative 
pediatric cancer treatment groups to form the Children's Oncology Group (COG). New 
protocols for children with soft tissue sarcoma are developed by the Soft Tissue 
Sarcoma Committee of the COG (COG-STS). Current COG-STS protocols for 
rhabdomyosarcoma use the TNM-based pretreatment staging system that incorporates 
the primary tumor site, presence or absence of tumor invasion of surrounding tissues, 
tumor size, regional lymph node status, and the presence or absence of metastases (51, 
52). After patients are categorized by Stage and Surgical-pathologic Group, a Risk 
Group is assigned. This takes into account Stage, Group, and histology. Patients are 
classified for protocol purposes as having a low risk, intermediate risk, or high risk of 
disease recurrence (53, 54). Treatment assignment is based on Risk Group. 
 
Treatment Option Overview 
All children with rhabdomyosarcoma should receive chemotherapy. The intensity and 
duration of the chemotherapy are dependent on the Risk Group assignment. All children 
with rhabdomyosarcoma require multimodality therapy with systemic chemotherapy, in 
conjunction with either surgery, radiation therapy (RT), or both modalities to maximize 
local tumor control (55-57).  
Surgical resection may be performed prior to chemotherapy if it will not result in 
disfigurement, substantial functional compromise, or organ dysfunction. In most cases, 
this is not possible, and therefore, only an initial biopsy is performed. The majority of 
patients have Group III (gross residual) disease.  
After initial chemotherapy, Group III patients receive definitive RT for control of the 
primary tumor. Some patients with initially unresected tumors may undergo second-
look surgery (delayed primary excision) to remove residual tumor. This is most 
appropriate if the delayed excision is deemed feasible with acceptable 
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functional/cosmetic outcome, and if a modest reduction in radiation dose is expected to 
significantly reduce the risk of long-term adverse effects. RT is given to clinically 
suspicious lymph nodes (detected by palpation or imaging) unless the suspicious lymph 
nodes are biopsied and shown to be free of rhabdomyosarcoma.  
The treatment of rhabdomyosarcoma by the Children's Oncology Group (COG) and in 
Europe (as exemplified by trials from the Intergroup Rhabdomyosarcoma Study Group 
[IRSG], the Soft Tissue Sarcoma Committee of the COG [COG-STS], and the 
International Society of Pediatric Oncology Malignant Mesenchymal Tumor [MMT] 
Group) differs in management and overall treatment philosophy (56). Children are 
treated with a more or less intense CT according to risk group. Main drugs are 
Ifosfamide, Actinomicine, Vincristine and Doxorubicine. 
 
Leptomeningeal dissemination of cancer 
 
Neoplastic meningitis results from the spread of malignant cells to leptomeninges and 
subarachnoid space and their dissemination within the cerebrospinal fluid (CSF) 
compartment. Malignant cells may reach the subarachnoid space through the blood 
(arterial or venous), by growing along nerve and vascular sheeths, by migration from a 
tumor adjacent to CSF or by iatrogenic spread of tumor cells following resection of 
metastasis (58, 59).  
Neoplastic meningitis is a devasting complication of both solid and hematologic tumors 
and is estimated to occur in 5-8% of cancer patients. Among adults the most common 
cancers that metastasize to the leptomeninges are breast cancer, lung cancer, melanoma, 
lymphomas and leukemias; in the pediatric population leukemia is the most common 
cancer with predilection for leptomeningeal dissemination; however primary central 
nervous system tumors (medulloblastoma and glioma), other cancers like 
neuroblastoma, rhabdomyosarcoma and retinoblastoma may also disseminate to the 
leptomeninges (60).  
Despite treatment the median survival duration for patients with neoplastic meningitis is 
in the range of 8-16 weeks. The impact of neoplastic meningitis is likely to increase in 
the future as advances in systemic treatment have improved survival but leave the 
leptomeninges and CSF a sanctuary site (61). The meninges are a sanctuary site because 
protected by the blood brain barrier (BBB) from the cytotoxic effects of systemic 
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anticancer therapy. The BBB often prevents efficient penetration of many drugs into the 
CSF space so that only few systemic chemotherapy agents can produce clinically 
relevant CSF concentrations and only at high doses; this could produce significant 
systemic toxicity. Regional delivery of drugs directly into the CSF is pharmacologically 
advantageous, with small doses producing high CSF concentration with minimal 
systemic exposure (62). Unfortunately only a limited number of drugs have been found 
to be safe and efficacious when administered by the intrathecal (IT) route. 
Therapeutic approaches for leptomeningeal dissemination of cancer are:  
- Radiotherapy (RT) 
- Systemic CT 
- I.T. CT 
 
Focal RT is performed in the treatment of bulky disease and in patients with CSF flow 
blocks. In addition focal RT should also be administered to symptomatic areas with a 
short palliative schedule. Another use of RT is in the treatment of cauda equina 
syndrome and cranial neuropathies from neoplastic meningitis, whereas craniospinal 
irradiation is rarely used because of significant systemic toxicity (63). 
 
Systemic CT efficacy is not affected by CSF flow obstruction if compared to IT CT. 
However systemic CT can be limited by systemic toxicity because it’s necessary to 
administer high doses to reach a clinically relevant CSF concentrations; another 
difficulty is using an effective treatment for neoplastic meningitis as well as for the 
underlying disease causing the meningeal spread. High doses methotrexate (MTX) have 
favorable CSF penetration but considerable systemic toxicity too; moreover MTX is not 
typically part of standard regimens used to treat many of the underlying tumors, making 
its incorporation into systemic treatment difficult. Ifosfamide and topotecan are both 
active but toxic, like MTX. Oral temozolomide and capecitabine have shown interesting 
results against leptomeningeal dissemination from breast and lung cancer (63). 
 
Intrathecal chemotherapy  
 
CT administration can be undertaken either I.T. via a lumbar puncture (LP) or via an 
intraventricular device with a catheter into the lateral ventricle by Ommaya reservoir.  
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IT CT has been used in the treatment of leptomeningeal dissemination even though the 
extent of its benefit has not been proven in randomized controlled trials and some 
studies showed discordant evidence. IT treatment offers local therapy with minimum 
systemic toxicity, and avoiding the BBB drugs are distributed throughout the entire 
subarachnoid space; although high drug concentrations could be achieved in the CSF, 
IT CT is not effective for bulky disease in the meninges because intra-CSF agents 
penetrate only 2-3 mm into such lesions (63).  
IT administration of anticancer drugs has been an effective strategy for the primary 
treatment and prevention of leptomeningeal leukemias and lymphomas, but it has not 
been effective in patients with neoplastic meningitis from solid tumors or in patients 
with refractory leptomeningeal leukemias (this results in part from the limited number 
of agents available for IT administration) (64).  
Only a small number of anticancer agents are regularly used: methotrexate, cytarabine, 
liposomal cytarabine, thiotepa. None of these have resulted in significantly prolonged 
survival and combination of intra-CSF drugs have not improved outcomes over single 
agents (61). MTX and liposomal cytarabine are the IT drugs most commonly used for 
leptomeningeal dissemination in solid tumors. However in the few randomized trials the 
data were discordant when comparing treatments (65). No one have a significant impact 
on survival, in the studies available “time to neurological progression” is the most 
frequently used parameter to evaluate response to treatment; the most common adverse 
event during IT CT is arachnoiditis/chemical meningitis (66, 67).  
Then neoplastic meningitis is still a relevant clinical problem, therefore it is essential to 
develop new IT agents with novel mechanism of action. In the last few years various 
experimental IT drugs have been reported upon from small clinical trials, a few case 
reports, and preclinical studies.  
Among them Topotecan showed interesting results. 
 
Intrathecal Topotecan  
 
Topotecan is a topoisomerase I poison that has anticancer activity against a variety of 
adult and childhood solid tumors. Preclinical studies demonstrated a good CSF 
penetration capability; 0,1 mg intraventricular dose (equivalent to 1 mg in humans) was 
defined as a well tolerated dose (68, 69).  
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The results of these preclinical studies served as the basis for phase I studies of IT 
topotecan in patients with neoplastic meningitis. The phase I study conducted by Blaney 
and colleagues (64) proved the feasibility of administering topotecan at 0,4 mg as 
maximum tolerated dose (MTD) to children and adults with neoplastic meningitis (17 
assessable patients, heterogenous histotypes); arachnoiditis was the dose limiting 
toxicity (DLT). A second phase I study (60) aimed to re-evaluate the dosing schedule 
for IT topotecan administration based upon preclinical evidence that the antitumor 
activity of topoisomerase I inhibitors is schedule dependent (70, 69). 19 patients <22 
years with leukemias and central nervous system cancer were enrolled. The study 
demonstrated that intensified dosing of topotecan is feasible (with chemical 
arachnoiditis being the DLT) but whether shorter or longer duration of exposure to the 
drug would be superior or not is unknown. Because of many different tumor types 
enrolled, this study, as well as the first one, cannot make definitive conclusions 
regarding antitumor activity.  
A phase II study by Groves and colleagues (61) analyzed the results obtained with IT 
topotecan classic schedule administration in 62 adult patients with leptomeningeal 
dissemination from solid tumors. 40 patients were evaluable; treatment was well 
tolerated (arachnoiditis being the most common adverse event) but outcomes were no 
better than those reported in trials that employed other IV CT. Better results have been 
obtained by IT topotecan administered to 20 children with leptomeningeal leukemia 
(71): among 16 evaluable patients a 37,5% CR have been achieved with a confirmed 
mild toxicity. A phase II trial of IT topotecan was performed in children with 
dissemination to the meninges by medulloblastoma and other solid tumors (72); the 
treatment was well tolerated, there were no objective responses; however the authors 
observed a benefit in terms of disease stabilization greater than 5 months in 4 children.  
Data available show that:  
 leptomeningeal dissemination of tumors is a devasting problem because outcome is very 
bad and treatments available are very few;  
 data about IT topotecan come out studies with heterogeneous and small population of 
patients;  
 results in terms of RR/PFS/OS are disappointing but clinical benefit and stabilizations 
have been observed; 
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 at our knowledge no phase II studies have been performed with IT topotecan in patients 
with rhabdomyosarcoma-EPNET tumors and leptomeningeal spread.  
For this reason with designed a phase II study with IT topotecan in patients with 
rhabdomyosarcoma-EPNET tumors and leptomeningeal spread.   
 
RMS/EPNET with leptomeningeal dissemination enrolled in STSC protocols  
 
We have found 13 patients with leptomeningeal dissemination from RMS or Ewing 
PNET tumors enrolled in STSC clinical trials from 1979 to 2013.  
Analysis about clinical characteristics and outcome are on going. 
 
 
OBJECTIVES AND ENDPOINTS 
 
The primary objective is to determine the therapeutic activity of IT Topotecan in terms 
of Response rate and time to CNS progression in pediatric patients with RMS/EPNET 
tumors. 
The secondary endpoint  is to assess duration of response, overall survival, safety and 
toxicity. 
 
 
OVERALL STUDY PLAN 
 
STUDY DESIGN 
Multicenter, prospective, non randomized phase II trial. 
 
STUDY CENTERS 
Italy: Padova, INT Milano, Genova, Roma, Napoli, Bergamo, Torino... 
Europe: … 
 
EXPECTED NUMBER OF PATIENTS 
 
PATIENT REGISTRATION 
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STUDY PERIOD 
 
 
SUBJECT POPULATION AND SELECTION 
 
INCLUSION CRITERIA 
 Histologically confirmed RMS or Ewing PNET sarcoma with leptomeningeal 
involvement (see assessment of CNS dissemination) 
 CNS dissemination: positive CSF citology examination or unequivocal evidence of 
leptomeningeal disease on CT scan or MRI scan. 
 Patients < 21 years of age  
 Patients, parents or legal representatives must provide written informed consent 
 Life expectancy of at least 8 weeks 
 KPS > 60%  
 Adequate organ function: 
Adequate haematological function: haemoglobin ³ 80 g/l, neutrophil count ³ 1.0 x 109/L, 
platelet count ³ 100 x 109/L; in case of bone marrow disease: neutrophils ³ 0.5 x 109/l 
and platelets 75 x 109/l. 
Adequate renal function: normal creatinine related to patient’s age: 
o 0 – 1 year: 40 μmol/L 
o 1 – 15 years: 65 μmol/L 
o 15 – 20 years: 110 μmol/L 
Adequate hepatic function: bilirubin <1.5 x ULN; AST and ALT <2.5 x ULN (AST, 
ALT 5xULN in case of liver metastases) 
 Wash-out of 3-4 weeks in case of prior chemotherapy 
 Concurrent CT to control systemic disease is allowed if the systemic CT is not a phase I 
agent that significantly penetrates the CSF or an agent known to have serious 
unpredictable CNS side effects 
 Concurrent dexamethasone or prednisone allowed if part of a systemic CT regimen 
 At least 8 weeks since prior cranial irradiation and recovered 
 At least 14 days since prior investigational drug 
 Fertile patients must use effective contraception 
 72 
 
 Patient/family able to comply to the study protocol 
 
EXCLUSION CRITERIA 
• Clinical evidence of obstructive hydrocephalus   
• Serious concomitant systemic disorders 
• History of allergic reaction to study drug 
• Pregnant or breast feeding mothers 
• Concurrent whole brain or craniospinal irradiation 
 
 
TREATMENTS 
 
DOSING AND ADMINISTRATION 
Topotecan is supplied in 4 mg vials; the content of each vial is diluted in 4 ml of sterile 
water then further diluted with preservative free, pyrogen free saline to a final volume 
of 10 ml. Administration of the drug is performed at a constant rate of 2,0 ml/minute 
(total 5 minutes) through an intraventricular reservoir or lumbar puncture (LP). 
The volume of CSF equivalent to the volume of drug to be administered is removed 
prior to drug administration.  
Patients who receive topotecan via LP have to remain prone, flat or in the 
Trendelemburg position for 1 hour following drug administration. After drug 
administration via an intraventricular reservoir, the reservoir has to be flushed slowly 
for 1-2 minutes with approximately 2 ml of either CSF or preservative free normal 
saline then pumped 4-6 times.  
Treatment:  
• Induction: Topotecan IT 0,4 mg/dose twice weekly for 6 weeks 
• Consolidation: Topotecan IT 0,4 mg/dose weekly for 4 weeks 
• Maintenance: Topotecan IT 0,4 mg/dose twice monthly for 4 months then monthly 
through year 1 
 
TREATMENT DURATION 
The maximum planned treatment duration in absence of toxicity or progression is up to 
2 years. 
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FOLLOW-UP 
The follow-up period begins when the patient discontinues from study treatment. 
If feasible, one post-discontinuation visit will be performed 30 days after treatment 
discontinuation and follow-up in all patients must be pursued every 2 months until the 
patient's death or up to at least one year until study cut-off.  
Patients with adverse events at the end of the study related to treatment must be 
followed until recovery. 
During post-therapy follow-up, information will be collected in the CRF regarding date 
of disease progression, further second line treatment (chemo, radiotherapy, surgery) and 
death. The date of first documented disease progression must be recorded on the CRF 
even if it occurs after the patient has started a new therapy. All deaths will be recorded. 
 
TREATMENT DISCONTINUATION 
Treatment should be discontinued if this is considered to be in the best interest of the 
patient. Treatment could be discontinued for the following reasons: 
 Investigator’s decision: if this decision is made because of toxicity, a serious adverse 
event, or a clinically significant laboratory value, appropriate measures will be taken 
and IGR will be notified immediately. 
 The patient, parents or legal representative’s refusal, withdrawal of patient consent. 
 The investigator or sponsor, for significant safety or efficacy reason, stops the study or 
stops the patient's participation in the study. 
 Evidence of progressive disease exists. 
 The patient becomes pregnant or fails to use adequate birth control (for those patients 
who are able to conceive). 
 The patient is non compliant with study procedures. 
 Life threatening toxicity. 
 Unmanageable or unacceptable toxicity, including the need for more than 2 dose 
reductions, except in cases of obvious patient benefit in continuing the treatment. 
 Treatment delay of more than 3 weeks for any reason except in cases of obvious 
patient benefit in continuing the treatment. 
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Study discontinuation, must be reported to IGR as soon as possible and immediately in 
case of discontinuation related to a serious adverse event. The primary reason and date 
of removal for all patients will be documented on the case report form (e.g. lost to 
follow-up, withdrawal of consent, patients wrongly included, adverse events, etc.). The 
final evaluation required by the protocol will be performed at the time of study 
discontinuation. Further follow-up should be reported. The investigator will attempt to 
complete all discharge procedures at the time a patient is removed from the treatment. 
 
CONCOMITANT THERAPIES 
Patients could receive chemotherapy to control systemic disease provided the systemic 
CT is not a phase I agent, doesn’t significantly penetrate the CSF, or is not known to 
have serious unpredictable CNS side effects.   
Patients are allowed to receive full supportive care therapies concomitantly during the 
study.  
If during the study patient develops a need for palliative radiotherapy, it should be 
ensured that this is not a manifestation of progressive disease (patients with progressive 
disease must discontinue study therapy). Palliative radiotherapy may be given for 
control of pain or for other reasons with no curative intent. The irradiated area cannot be 
used as a parameter for response assessment. 
 
 
EFFICACY AND SAFETY ASSESSMENTS 
 
The following exams will performed according to the schedule of assessments after 
signature of written informed consent by patients or parents or legal representative. 
 
CLINICAL ASSESSMENTS 
 
Medical History 
 Relevant past medical history, and current medical conditions not related to the current 
indication or disease for which patient entered into the study 
 Information related to diagnosis of the disease under study 
 Previous surgery, radiotherapy, systemic therapy, investigational therapy 
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Any disease related symptoms present at baseline. 
 
Physical examination 
 Physical and Neurological Examination 
 ECOG Performance Status or Lansky-Play score 
 Vital signs (pulse, blood pressure, temperature) 
 Height, Weight and Body Surface 
Will be done within 7 days before study enrolment, then before each administration 
 
LABORATORY AND TUMOR ASSESSMENTS 
 CSF studies: cell count, differential, protein, glucose. CSF citology: at baseline and at 
each CT administration 
 CT or MRI scans: at baseline, every 2 months and at the first post-discontinuation visit. 
 MRI of the spine if clinically indicated. 
 Bone marrow aspirates: at baseline 
 Pregnancy test (urine or serum) in females of childbearing potential within 7 days 
before study enrolment. 
 Complete Blood Count: leukocyte, neutrophil, platelets and haemoglobin within 7 days 
before study enrolment, then once a week during each cycle and every 2 days in case of 
neutro- or thrombocytopenia, and if possible at the first post-discontinuation visit 
 Serum Biochemistry: sodium, potassium, calcium, total protein, creatinine, urea, AST 
(SGOT), ALT (SGPT), total bilirubin, albumin within 7 days before study enrolment, 
then once a week, and if possible at the first post-discontinuation visit. 
 
SAFETY ASSESSMENTS 
Adverse events are evaluated according to NCI common toxicity criteria (vers 3.0). 
Treatment has to be stopped if there is >grade 3 non hematologic toxicity considered to 
be at least possibly related to topotecan with the following exception: >grade 3 
headache prevented after subsequent doses using premedication or >grade 3 nausea or 
vomiting that is well controlled or prevented after subsequent doses with antiemetics. 
After the routine use of dexamethasone patients with arachnoiditis could not receive 
further topotecan. 
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Any non hematologic toxicity experienced during a cycle must resolve to Grade 1 or 
lower before the next cycle may be administered. 
 
CRITERIA FOR ASSESSMENT OF RESPONSE 
Response is classified as complete response (CR), stable disease (SD) or progressive 
disease (PD). 
For CR patients need to have complete clearing of malignant cells from lumbar or 
ventricular CSF on two consecutive citologic studies at least 4 weeks apart, with no 
worsening of physical or neurological findings clearly attributable to neoplastic 
meningitis; complete clearing of disease on two consecutive MRI scans >4 weeks apart. 
PD is defined as the occurence of new malignant cells in the CSF on two consecutive 
occasions at least 1 week apart from after at least 3 previous consecutive negative CSF 
cytologist obtained at least 1 week apart or an increase of >25% in the size of 
measurable lesions on MRI or new lesions on MRI after a CR.  
Patients are considered to have stable disease (SD) if they don’t meet the criteria for 
either a CR or PD and without worsening of physical findings clearly attributable to 
disease. 
 
 
ADVERSE EVENTS 
 
It is of the utmost importance that all staff involved in the study are familiar with the 
content of this section. The principal investigator is responsible for ensuring this. 
 
ADVERSE EVENT 
Definition 
An adverse event (AE) is the development of an undesirable medical condition or the 
worsening of a preexisting medical condition in a clinical investigation subject. The 
event need not necessarily have a causal relationship with study drug and can occur at 
any time, including run-in or wash-out periods, even if no study treatment has been 
administered. An undesirable medical condition can be symptoms (eg, nausea, chest 
pain), signs (eg, tachycardia, enlarged liver) or the abnormal results of an investigation 
(eg, laboratory findings, x-ray, ECG). 
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Recording of Adverse Events 
When to collect AEs: any AE that occur from the time consent is given, during the 
study and in the 30 days following the last administration of study treatment should be 
recorded. 
What AE to collect: all observed AEs regardless of treatment group or suspected causal 
relationship to study drug will be assessed following NCI-CTC Criteria and recorded on 
the AE page(s) of the CRF, and in case of serious adverse event in a SAE form too. 
Worsening/exacerbation of sign and symptoms (in terms of severity and/or frequency, 
or the appearance of new manifestations/complications) of the malignancy under study 
or of a pre-existing illness should be reported as AE in the appropriate section of the 
CRF.  
Lack of or insufficient clinical response, benefit, efficacy, therapeutic effect, or 
pharmacological action, should not be recorded as an AE.  
The investigator must make the distinction between exacerbation of preexisting illness 
and lack of therapeutic efficacy. In addition, clinically significant changes in physical 
examination findings and abnormal objective test findings (e.g., x-ray, ECG) should 
also be recorded as AE.  
For all AEs, the investigator must pursue and obtain adequate information both to 
determine the outcome of the AE and to assess whether it meets the criteria for 
classification as a SAE requiring immediate notification to IGR. For all AEs, sufficient 
information should be obtained by the investigator to determine the causality of the AE 
(i.e., study drug or other illness). The investigator is required to assess causality and 
indicate that assessment on the CRF. All AEs and specially those that are serious, 
suspected to be related to study drug or considered significant by the investigator or 
clinical monitor must be followed after the time of therapy discontinuation until the 
event or its sequelae resolve or stabilize at a level acceptable to the investigator and the 
clinical monitor or his/her designated representative. 
All AEs will be recorded in the Case Reporting Form (CRF). 
 
SERIOUS ADVERSE EVENT 
SAE definition 
A Serious Adverse Event (SAE) is any adverse event occurring at any dose that: 
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· Is fatal (results in death). 
· Is life-threatening. 
· Requires or prolongs inpatient hospitalization. 
· Results in persistent or significant disability/incapacity. 
· Is a congenital anomaly/birth defect. 
· Is medically significant or requires intervention to prevent one of the outcomes listed 
above.  
Any clinical event or laboratory result considered serious by the investigator and not 
corresponding to the criteria of seriousness defined above is nevertheless considered to 
be medically significant. Such an event/result can carry a risk for the patient and can 
require medical intervention to prevent one of the outcomes listed above (i.e. overdoses, 
second cancer and pregnancies can be considered medically significant). Medical and 
scientific judgment should be exercised in deciding whether other situations such as 
important medical events that may not be immediately life-threatening or result in 
hospitalization but may jeopardize the safety of the patient or may require intervention 
to prevent one of the outcomes listed in the definition above. 
A life-threatening AE is any adverse drug experience that places the patient/subject at 
immediate risk of death from the reaction as it occurred, i.e., it does not include a 
reaction that, had it occurred in a more severe form, might have caused death. 
Hospitalization is defined as in-patient hospital admission associated with an AE which 
occurs or worsens after the patient has been included in study. Thus attendance/ 
treatment at an emergency room/outpatient department does not meet hospitalization 
SAE criteria. However, an event which results in attendance / treatment at such a 
facility is an SAE if it is considered medically significant or required intervention to 
prevent one of the other seriousness criteria. 
Note: The SAE is the diagnosis or sign /symptom, NOT the procedure or test defined as 
any inpatient admission. 
Inpatient admission in the absence of a precipitating, treatment-emergent, clinical AE 
may meet criteria for “seriousness” but is not an adverse experience and thus is not 
subject to immediate reporting to IGR.  
Prolongation of hospitalization is defined as any extension of an inpatient 
hospitalization beyond the stay anticipated/required in relation to the original reason for 
the initial admission, as determined by the investigator or treating physician. For 
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protocol-specified hospitalizations in clinical trials, prolongation is defined as any 
extension beyond the length of stay described in the protocol. Prolongation in the 
absence of a precipitating, treatment-emergent, clinical AE (i.e., not associated with the 
development of a new AE or worsening of a pre-existing condition) may meet criteria 
for "seriousness" but is not an adverse experience and thus is not subject to immediate 
reporting to IGR. Pre-planned treatments or surgical procedures should be noted in the 
baseline documentation for the entire protocol and/or for the individual patient/subject. 
Disability is a substantial disruption of a person’s ability to conduct normal life 
functions. 
 
SAEs reporting 
Any SAE or SUSAR as defined above which occurs or comes to the attention of the 
investigator at any time during the study and through 30 days after the last 
administration of study drug, independent of the circumstances or suspected cause, must 
be reported immediately, within 24 hours of knowledge by fax via a SAE form. 
The Pharmacovigilance Unit at IGR will assess the adverse events in terms of 
seriousness, expectedness (IB), severity (NCI-CTCAE v3.0) and relationship to the 
study drug. All SAEs will be coded using medDRA. 
Assessment of causality of SAEs may be reviewed during the study by the study 
coordinator. Information collected in the SAE form is crucial to assess the case and for 
this reason diligence in collecting as much verifiable and reliable information: BOTH 
QUALITY and TIMELINES are key factors.  
All SAEs should be reported immediately (within 24 hours of knowledge of the event), 
regardless of time elapsed since last study drug dose (until 30 days after the last 
administration of study drug). The investigator must provide any relevant information 
for the required 8 days follow up report for any SAE which is fatal or life threatening. 
As far as possible, for each event, the following should be noted: 
1. As clear as possible a description in medical terminology to allow for a complete 
medical assessment of the case and independent determination of possible causality 
2. Its duration (start and end dates) 
3. Action taken and the necessity for corrective treatment or not, stoppage of study 
drug(s) or not, and so on 
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4. Its intensity (grade 1-5), according to the NCI/NIH Common Terminology Criteria 
AE version 3.0 (a copy can be downloaded from the CTEP home page: 
http://ctep.info.nih.gov). 
5. Its relationship to the study drug or treatment, the pathology treated, another 
pathology or another treatment, or to a constraint linked to the research (period without 
treatment, further tests required for the research, and so on). If causality is unknown and 
the investigator does not know whether or not study drug caused the event, it should be 
attributed to study drug. If the investigator's causality assessment is "unknown but not 
related to study drug", this should be clearly documented on study records. 
6. Documentation of all co-medication and/or therapies 
7. Documentation of all relevant medical history and/or co-existing diseases 
8. The outcome (where applicable).  
For non fatal events, developments should be followed up until either recovery or 
recovery of a previous state of health or until the stabilization of possible aftereffects. 
The investigator must also attach the following to the serious adverse event report form, 
wherever possible: 
· A copy of the summary of hospitalization or prolongation of hospitalization 
· A copy of the post-mortem report 
· A copy of all laboratory examinations and the dates on which these examinations were 
carried out, including relevant negative results, as well as normal laboratory ranges. 
· All other document that he judges useful and relevant. 
All these documents will remain anonymous. 
Further information can be requested (by fax, telephone or when visiting) by the 
monitor and/or the safety manager. All SAEs will be recorded in the Case Reporting 
Form (CRF) too. 
 
Adverse events follow-up 
The investigator is responsible for the appropriate medical follow-up of patients until 
resolution or stabilization of the adverse event or until the patient's death. This may 
mean that follow-up should continue once the patient has left the trial. Follow up 
information about a previously reported serious adverse event must be reported by the 
investigator to the pharmacovigilance unit within 48 hours of receiving it. 
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The investigator also transmits the final report at the time of resolution or stabilization 
of the SAE. He retains the documents concerning the supposed adverse event so that 
previously transmitted information can be completed if necessary. 
 
Annual safety report 
The pharmacovigilance unit at IGR will issue once a year throughout the clinical trial, 
or on request, the annual safety report (ASR) of the study, in accordance with the 
detailed guidance issued by the European Commission on the collection, verification 
and presentation of adverse reaction reports arising from clinical trials on medicinal 
products for human use of April 2006 and the applicable revisions thereof. The 
pharmacovigilance unit will send a copy of the ASR to the investigators and national 
sponsors. Each national sponsor should submit the ASR within 60 days of the data lock 
point (date of the first authorisation of the concerned clinical trial by a competent 
authority in a member state) to the national competent authority and the national Ethic 
Committee of the concerned Member State, according to national legislation. 
 
 
STATISTICAL CONSIDERATIONS 
TRIAL PLAN AND SAMPLE SIZE 
ANALYSIS 
DATA MANAGEMENT 
 
DATA COLLECTION, QUALITY ASSURANCE, MANAGEMENT 
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